Boston Scientific (BSX) 10-K 23 Feb 23 2022 FY Annual report Financial data

Cover

Cover - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Jan. 31, 2023	Jun. 30, 2021
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	1-11083
Entity Registrant Name	BOSTON SCIENTIFIC CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2695240
Entity Address, Address Line One	300 Boston Scientific Way
Entity Address, City or Town	Marlborough
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01752-1234
City Area Code	508
Local Phone Number	683-4000
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 53,200
Entity Listing, Par Value Per Share	$ 0.01
Entity Common Stock, Shares Outstanding		1,434,780,104
Entity Central Index Key	0000885725
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false
Common Stock [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	BSX
Security Exchange Name	NYSE
Senior Note due 2027 [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.625% Senior Notes due 2027
Trading Symbol	BSX27
Security Exchange Name	NYSE
5.50% MCPS, Series A [Member]
Entity Information [Line Items]
Title of 12(b) Security	5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share
Trading Symbol	BSX PR A
Security Exchange Name	NYSE

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2022
Audit Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Firm ID	42
Auditor Location	Boston, Massachusetts

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net sales	$ 12,682	$ 11,888	$ 9,913
Cost of products sold	3,956	3,711	3,465
Gross profit	8,727	8,177	6,448
Operating expenses:
Selling, general and administrative expenses	4,520	4,359	3,787
Research and development expenses	1,323	1,204	1,143
Royalty expense	47	49	45
Amortization expense	803	741	789
Goodwill impairment charges	0	0	73
Intangible asset impairment charges	132	370	460
Contingent consideration net expense (benefit)	35	(136)	(100)
Restructuring net charges (credits)	24	40	52
Litigation-related net charges (credits)	173	430	278
Gain (Loss) on Disposition of Assets	22	(78)	0
Operating expenses	7,078	6,978	6,528
Operating income (loss)	1,649	1,199	(80)
Other income (expense):
Interest expense	(470)	(341)	(361)
Other, net	(38)	218	362
Income (loss) before income taxes	1,141	1,076	(79)
Income tax expense (benefit)	443	36	2
Net income (loss)	698	1,041	(82)
Preferred stock dividends	55	55	33
Net income (loss) available to common stockholders	$ 642	$ 985	$ (115)
Net income (loss) per common share — basic	$ 0.45	$ 0.69	$ (0.08)
Net income (loss) per common share — assuming dilution	$ 0.45	$ 0.69	$ (0.08)
Weighted-average shares outstanding
Basic	1,430,500	1,422,300	1,416,700
Assuming dilution	1,439,700	1,433,800	1,416,700

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net income (loss)	$ 698	$ 1,041	$ (82)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(94)	(125)	76
Net change in derivative financial instruments	63	170	(137)
Net change in defined benefit pensions and other items	37	11	(1)
Total other comprehensive income (loss)	6	56	(63)
Total comprehensive income (loss)	$ 704	$ 1,096	$ (145)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 928	$ 1,925
Trade accounts receivable, net	1,970	1,778
Inventories	1,867	1,610
Prepaid income taxes	264	205
Other current assets	731	799
Total current assets	5,760	6,317
Property, plant and equipment, net	2,446	2,252
Goodwill	12,920	11,988
Other intangible assets, net	5,902	6,121
Deferred tax assets	3,942	4,142
Other long-term assets	1,500	1,410
TOTAL ASSETS	32,469	32,229
Current liabilities:
Current debt obligations	20	261
Accounts payable	862	794
Accrued expenses	2,160	2,436
Other current liabilities	761	783
Total current liabilities	3,803	4,274
Long-term debt	8,915	8,804
Deferred tax liabilities	144	310
Other long-term liabilities	2,035	2,220
Commitments and contingencies
Preferred Stock, Shares Issued	10,062,500	10,062,500
Stockholders’ equity:
Preferred stock, $0.01 par value - authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2022 and 2021	$ 0	$ 0
Common stock, $0.01 par value - authorized 2,000,000,000 shares; issued 1,696,633,993 shares as of December 31, 2022 and 1,688,810,052 shares as of December 31, 2021	$ 17	$ 17
Treasury Stock, Shares	263,289,848	263,289,848
Treasury stock, at cost - 263,289,848 shares as of December 31, 2022 and 2021	$ (2,251)	$ (2,251)
Additional paid-in capital	20,289	19,986
Accumulated deficit	(750)	(1,392)
Accumulated Other Comprehensive Income (Loss), Net of Tax	269	263
Total stockholders’ equity	17,573	16,622
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 32,469	$ 32,229

Consolidated Balance Sheet Para

Consolidated Balance Sheet Paranthetical - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Consolidated Balance Sheet (Parenthetical) [Abstract]
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	50,000,000	50,000,000
Preferred Stock, Shares Issued	10,062,500	10,062,500
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000
Common Stock, Shares, Issued	1,696,633,993	1,688,810,052
Treasury Stock, Shares	263,289,848	263,289,848

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Shares, Issued at Dec. 31, 2019		0	1,642,488,911
Total Stockholders' Equity at Dec. 31, 2019		$ 0	$ 16	$ (1,717)	$ 17,561	$ (2,253)	$ 270
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issuance (Shares)		10,062,500	29,382,500
Stock-based compensation (Shares)			8,040,507
Stock Issuance (Par value)		$ 0	$ 0
Treasury Stock, Value, Acquired, Cost Method				(535)
Preferred stock issuance (Value in excess of par)					975
Common stock issuance (Value in excess of par)					975
Stock-based compensation			$ 0		221
Net income (loss)	$ (82)					(82)
Cumulative effect adjustment for adoption of ASC 2016-13	10					(10)
Preferred stock dividends						(33)
Ending Balance (Shares Issued) at Dec. 31, 2020		10,062,500	1,679,911,918
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	76						76
Net change in derivative financial instruments	(137)						(137)
Net change in defined benefit pensions and other items	1						(1)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2020	$ 15,326	$ 0	$ 17	(2,251)	19,732	(2,378)	207
Other comprehensive income (loss), net of tax:
Common Stock, Shares, Issued	1,679,911,918
Stock issuance (Shares)		0	0
Stock-based compensation (Shares)			8,898,134
Stock Issuance (Par value)		$ 0	$ 0
Treasury Stock, Value, Acquired, Cost Method				0
Preferred stock issuance (Value in excess of par)					0
Common stock issuance (Value in excess of par)					0
Stock-based compensation			$ 0		254
Net income (loss)	$ 1,041					1,041
Cumulative effect adjustment for adoption of ASC 2016-13						0
Preferred stock dividends						(55)
Ending Balance (Shares Issued) at Dec. 31, 2021		10,062,500	1,688,810,052
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(125)						(125)
Net change in derivative financial instruments	170						170
Net change in defined benefit pensions and other items	(11)						11
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2021	$ 16,622	$ 0	$ 17	(2,251)	19,986	(1,392)	263
Other comprehensive income (loss), net of tax:
Common Stock, Shares, Issued	1,688,810,052
Stock issuance (Shares)		0	0
Stock-based compensation (Shares)			7,823,941
Stock Issuance (Par value)		$ 0	$ 0
Treasury Stock, Value, Acquired, Cost Method				0
Preferred stock issuance (Value in excess of par)					0
Common stock issuance (Value in excess of par)					0
Stock-based compensation			0		303
Net income (loss)	$ 698					698
Cumulative effect adjustment for adoption of ASC 2016-13						0
Preferred stock dividends						(55)
Ending Balance (Shares Issued) at Dec. 31, 2022		10,062,500
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(94)						(94)
Net change in derivative financial instruments	63						63
Net change in defined benefit pensions and other items	(37)						37
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2022	$ 17,573	$ 0	$ 17	$ (2,251)	$ 20,289	$ (750)	$ 269
Other comprehensive income (loss), net of tax:
Common Stock, Shares, Issued	1,696,633,993

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net income (loss)	$ 698,000,000	$ 1,041,000,000	$ (82,000,000)
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities
Loss (gain) on disposal of businesses and assets	22,000,000	(78,000,000)	0
Depreciation and amortization	1,136,000,000	1,093,000,000	1,123,000,000
Deferred and prepaid income taxes	(63,000,000)	(124,000,000)	(82,000,000)
Stock-based compensation expense	220,000,000	194,000,000	170,000,000
Goodwill and other intangible asset impairment charges	132,000,000	370,000,000	533,000,000
Net loss (gain) on investments and notes receivable	1,000,000	(250,000,000)	(333,000,000)
Contingent consideration net expense (benefit)	35,000,000	(136,000,000)	(100,000,000)
Inventory step-up amortization	32,000,000	34,000,000	58,000,000
Debt extinguishment costs	194,000,000	0	0
Other, net	125,000,000	78,000,000	244,000,000
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:
Trade accounts receivable	(220,000,000)	(279,000,000)	335,000,000
Inventories	(321,000,000)	(346,000,000)	(65,000,000)
Other assets	(209,000,000)	(134,000,000)	(265,000,000)
Accounts payable, accrued expenses and other liabilities	(255,000,000)	408,000,000	(28,000,000)
Cash provided by (used for) operating activities	1,526,000,000	1,870,000,000	1,508,000,000
Investing Activities
Purchases of property, plant and equipment and internal use software	(588,000,000)	(554,000,000)	(376,000,000)
Proceeds from sale of property, plant and equipment	12,000,000	14,000,000	12,000,000
Payments for acquisitions of businesses, net of cash acquired	(1,542,000,000)	(2,258,000,000)	(3,000,000)
Proceeds from disposal of certain businesses and assets	5,000,000	826,000,000	15,000,000
Proceeds from royalty rights	70,000,000	82,000,000	87,000,000
Proceeds from (payments for) settlements of hedge contracts	56,000,000	15,000,000	0
Proceeds from (payments for) investments and acquisitions of certain technologies	(24,000,000)	279,000,000	(146,000,000)
Cash provided by (used for) investing activities	(2,011,000,000)	(1,597,000,000)	(411,000,000)
Financing Activities
Payment of contingent consideration previously established in purchase accounting	(335,000,000)	(15,000,000)	(49,000,000)
Payments for royalty rights	(75,000,000)	(85,000,000)	(97,000,000)
Payments on short-term borrowings	(250,000,000)	0	(2,950,000,000)
Proceeds from short-term borrowings, net of debt issuance costs	0	0	2,245,000,000
Net increase (decrease) in commercial paper	(1,000,000)	0	(714,000,000)
Payments on borrowings from credit facilities	0	0	(1,919,000,000)
Proceeds from borrowings on credit facilities	0	0	1,916,000,000
Payments on long-term borrowings and debt extinguishment costs	(3,184,000,000)	0	(1,260,000,000)
Proceeds from long-term borrowings, net of debt issuance costs	3,270,000,000	0	1,683,000,000
Cash dividends paid on preferred stock	(55,000,000)	(55,000,000)	(28,000,000)
Net proceeds from issuance of preferred stock in connection with public offering	0	0	975,000,000
Net proceeds from issuance of common stock in connection with public offering	0	0	975,000,000
Payments for repurchase of common stock	0	0	(535,000,000)
Cash used to net share settle employee equity awards	(53,000,000)	(50,000,000)	(59,000,000)
Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans	136,000,000	110,000,000	111,000,000
Cash provided by (used for) financing activities	(548,000,000)	(95,000,000)	293,000,000
Effect of foreign exchange rates on cash	(9,000,000)	(6,000,000)	(2,000,000)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents	(1,042,000,000)	173,000,000	1,388,000,000
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period	2,168,000,000	1,995,000,000	607,000,000
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	1,126,000,000	2,168,000,000	1,995,000,000
Supplemental Information
Income Taxes Paid	662,000,000	302,000,000	207,000,000
Interest Paid, Excluding Capitalized Interest, Operating Activities	450,000,000	338,000,000	359,000,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases	0	440,000,000	0
Non-cash impact of transferred royalty rights	$ (70,000,000)	$ (82,000,000)	$ (87,000,000)

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows Consolidated Statement of Cash Flows (Supplemental Disclosure) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash and cash equivalents	$ 928,000,000	$ 1,925,000,000	$ 1,734,000,000
Restricted cash and restricted cash equivalents included in Other current assets	149,000,000	188,000,000	208,000,000
Restricted cash equivalents included in Other long-term assets	48,000,000	55,000,000	52,000,000
Cash, cash equivalents, restricted cash and restricted cash equivalents	$ 1,126,000,000	$ 2,168,000,000	$ 1,995,000,000	$ 607,000,000

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE A – SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation Our consolidated financial statements include the accounts of Boston Scientific Corporation and our subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE) . For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2022, 2021 or 2020. Basis of Presentation The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation S-X. Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars. Subsequent Events We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions and Strategic Investments , Note I – Commitments and Contingencies and Note J – Stockholders' Equity . Accounting Estimates To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to Critical Accounting Estimates included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and Cash Equivalents We record Cash and cash equivalents in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash. Restricted Cash Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in Other current assets within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee. Restricted Cash Equivalents Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in Other current assets within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents are included in Other long-term assets within our consolidated balance sheets are related to deferred compensation plans. Concentrations of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral. We record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account. We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2022, 2021 and 2020; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales. We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our Allowance for credit losses is adequate as of December 31, 2022; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase. Revenue Recognition We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers : • We have a contract with a customer that creates enforceable rights and obligations, • Promised products or services are identified, • The transaction price, or the amount we expect to receive, is determinable and • We have transferred control of the promised items to the customer. Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets. Deferred Revenue We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral. Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred. Variable Consideration We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates. We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above. Post-Implant Services We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to Selling, general and administrative expenses within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost. Warranty Obligations We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary. Inventories We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to Cost of products sold over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. During 2020, we recorded $149 million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID-19 pandemic and lower than forecasted demand for our products. We did not record any abnormal production variances during the years ended December 31, 2022 or 2021. We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory. Property, Plant and Equipment We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease. Valuation of Business Combinations We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through Selling, general and administrative expenses . In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in Other, net equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition. Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through Contingent consideration net expense (benefit) on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition. Indefinite-lived Intangibles and IPR&D Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&D intangible assets acquired in a business combination. Our IPR&D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&D intangible asset. We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other. If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value. We use the income approach to determine the fair values of our IPR&D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See Note C – Goodwill and Other Intangible Assets for more information related to indefinite-lived intangibles, including IPR&D. For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date. Amortization and Impairment of Intangible Assets We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20 years; amortizable technology-related and customer relationships, five to 25 years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets, and amortize over a two to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within Cost of products sold; Selling, general and administrative expenses and Research and development expenses, as appropriate within our accompanying consolidated statements of operations, and include in Amortization expense only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents. We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See Note C – Goodwill and Other Intangible Assets for more information related to impairments of intangible assets. For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent. Goodwill Valuation We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, Intangibles - Goodwill and Other , we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit. Investments in Publicly Traded and Privately-Held Entities For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in Other, net within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, Investments - Equity Method and Joint Ventures . We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320 , Investments - Debt and Equity Securities . Refer to Note B – Acquisitions and Strategic Investments for additional details on our investment balances. Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. Net gains and losses and impairments associated with our investment portfolio are included within Other, net in our consolidated statements of operations. Income Taxes We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See Note H – Income Taxes for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA. Legal and Product Liability Costs We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the

Acquisitions and Strategic Inve

Acquisitions and Strategic Investments	Aug. 06, 2021
Business Combinations [Abstract]
ACQUISITIONS AND STRATEGIC INVESTMENTS	NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS Our consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our consolidated financial statements. Further, transaction costs were immaterial to our consolidated financial statements and were expensed as incurred. On June 15, 2022, we announced our entry into a definitive agreement with Synergy Innovation Co, Ltd, to purchase its majority stake of M.I. Tech Co., Ltd., (M.I. Tech), a publicly traded Korean manufacturer and distributor of medical devices for endoscopic and urological procedures. The agreement, whereby we will purchase approximately 64 percent of the outstanding shares of M.I. Tech, consists of an upfront purchase price of KRW 291.2 billion or approximately $230 million at foreign currency exchange rates locked into at the time of the agreement via forward currency contracts. We are working towards closing the acquisition during the second quarter of 2023, subject to customary regulatory approvals. The M.I. Tech stent portfolio complements our existing Endoscopy portfolio which will provide physicians with more treatment options to meet specific patient needs. On November 29, 2022, we announced our entry into a definitive agreement to acquire 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The agreement provides for an upfront cash payment of $10.00 per share, approximately $615 million, and is expected to close during the first half of 2023, subject to customary closing conditions. The Apollo business will be integrated into our Endoscopy division. On February 20, 2023, we completed the acquisition of a majority stake in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons used in the treatment of vascular and other diseases. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or approximately $520 million at foreign currency exchange rates as of closing using cash on hand. The Acotec portfolio complements our existing Peripheral Interventions portfolio and will strengthen our presence in China. 2022 Acquisition On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which has developed the radiofrequency (RF) NRG™ and VersaCross™ Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expands our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $1.463 billion, net of cash acquired, subject to closing adjustments. We are integrating the Baylis Medical business into our Cardiology division. Purchase Price Allocation The final purchase price was comprised of the amount presented below: (in millions) Payment for acquisition, net of cash acquired $ 1,463 $ 1,463 The final purchase price allocation was comprised of the following components: (in millions) Goodwill $ 988 Amortizable intangible assets 657 Other assets acquired 112 Liabilities assumed (287) Net deferred tax liabilities (7) $ 1,463 Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies. We allocated a portion of the purchase price to the specific intangible asset categories as follows: Amount Assigned (in millions) Weighted Average Amortization Period (in years) Risk-Adjusted Discount Amortizable intangible assets: Technology-related $ 622 11 11% Other intangible assets 36 11 11% $ 657 Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives. 2021 Acquisitions On March 1, 2021, we completed our acquisition of Preventice Solutions, Inc. (Preventice), a privately-held company with a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment. We had been an investor in Preventice since 2015 and held an equity stake of approximately 22 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $196 million gain recognized within Other, net . The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and an additional revenue-based milestone payment of $216 million made during the second quarter of 2022. The Preventice business is being managed by our Cardiology division. On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately-held company that developed a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue-based payments over the next three years. We had been an investor in Farapulse since 2014 and held an equity stake of approximately 27 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within Other, net . The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, up to $92 million in additional clinical and regulatory milestone payments, as well as future revenue-based payments. We have made combined milestone and revenue based payments of $114 million to date. The Farapulse business is being integrated into our Cardiology division. On September 1, 2021, we completed our acquisition of the global surgical business of Lumenis LTD. (Lumenis), a privately-held company that has developed and commercialized energy-based medical solutions, including innovative laser systems, fibers and accessories used for urology and otolaryngology procedures. The transaction consisted of an upfront cash payment of $1.032 billion, net of cash acquired. The Lumenis business is being integrated into our Urology division. On November 8, 2021, we completed our acquisition of the remaining shares of Devoro Medical, Inc. (Devoro Medical), a privately-held company which has developed the WOLF Thrombectomy® Platform, a non-console and lytic-free platform designed to rapidly capture and extract blood clots in arterial, venous and pulmonary embolism procedures. The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones. We had been an investor in Devoro Medical since 2019 and held an equity stake of approximately 16 percent. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $57 million gain recognized within Other, net . The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments. The Devoro Medical business is being integrated into our Peripheral Interventions division. Purchase Price Allocation The final purchase price for the acquisitions completed during 2021 were comprised of the components presented below, which represents the determination of the fair value of identifiable assets acquired and liabilities assumed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations . (in millions) Preventice Lumenis All Other Total Payment for acquisition, net of cash acquired $ 706 $ 1,032 $ 519 $ 2,258 Fair value of contingent consideration 221 — 218 440 Fair value of prior interest 269 — 287 556 $ 1,197 $ 1,032 $ 1,025 $ 3,254 The final purchase price allocation for these acquisitions was comprised of the following components: (in millions) Preventice Lumenis All Other Total Goodwill $ 926 $ 534 $ 594 $ 2,053 Amortizable intangible assets 237 423 465 1,125 Indefinite-lived intangible assets — 69 43 112 Other assets acquired 65 297 9 372 Liabilities assumed (32) (282) (11) (325) Net deferred tax liabilities — (9) (75) (84) $ 1,197 $ 1,032 $ 1,025 $ 3,254 Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies. In 2022, we recorded certain measurement period adjustments primarily related to our prior year acquisition of the surgical business of Lumenis. We recorded an accrued income tax liability within Other non-current liabilities within our consolidated balance sheet of $183 million related to uncertain tax positions assumed in connection with the acquisition. We expect to be indemnified for the majority of such tax obligations and we recognized a corresponding indemnification asset of $177 million within Other non-current assets within our consolidated balance sheets. Interest and penalties accrued on the tax liability are being recorded within Income tax expense (benefit) and corresponding adjustments to the indemnification asset are being recorded in Other, net within our accompanying consolidated statements of operations. The outcome of these matters is subject to uncertainty and ultimately, the amount of tax due and the related indemnification reimbursement we receive will be dependent on the outcome of tax return examinations by relevant authorities. Refer to Note Note G – Supplemental Balance Sheet Information for further details regarding our indemnification asset. We allocated a portion of the purchase price to the specific intangible asset categories as follows: Amount Assigned (in millions) Weighted Average Amortization Period (in years) Risk-Adjusted Discount Preventice: Amortizable intangible assets: Technology-related $ 215 9 10% Other intangible assets 22 8 10% $ 237 Lumenis: Amortizable intangible assets: Technology-related $ 388 12 11% Other intangible assets 35 11 11% Indefinite-lived intangible assets: IPR&D 69 N/A 12% $ 492 All Other: Amortizable intangible assets: Technology-related $ 465 12 16% - 17% Indefinite-lived intangible assets: IPR&D 43 N/A 17% $ 508 2021 Divestiture On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800 million, subject to certain adjustments including cash on hand at the closing of the transaction. The agreement included the transfer of five facilities and approximately 280 employees globally. In 2020, we recorded Goodwill impairment charges of $73 million related to our Specialty Pharmaceuticals business and classified the remaining assets and liabilities as held for sale as of December 31, 2020. Contingent Consideration Changes in the fair value of our contingent consideration liability were as follows: (in millions) Balance as of December 31, 2020 $ 196 Amount recorded related to current year acquisitions 440 Contingent consideration net expense (benefit) (136) Contingent consideration payments (15) Balance as of December 31, 2021 $ 486 Contingent consideration net expense (benefit) 35 Contingent consideration payments (371) Balance as of December 31, 2022 $ 149 The payments made during 2022 were primarily related to our 2021 acquisitions of Farapulse and Preventice. As of December 31, 2022, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay associated with our completed acquisitions was approximately $417 million. The net expense of $35 million recorded in 2022 related to an increase in expected revenue-based payments as a result of over-achievement of net sales performance, primarily related to Farapulse. The net benefit of $136 million recorded in 2021 related to a reduction in the contingent consideration liability for certain prior acquisitions for which we reduced the probability of achievement of associated revenue and/or regulatory milestones upon which payment is conditioned, or, for milestones that would not be achieved due to management's discontinuation of the associated R&D program. Refer to Note C – Goodwill and Other Intangible Assets for further details. The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs: Contingent Consideration Liability Fair Value as of December 31, 2022 Valuation Technique Unobservable Input Range Weighted Average (1) R&D, Regulatory and Commercialization-based Milestones $13 million Discounted Cash Flow Discount Rate 1% - 2% 2% Probability of Payment 10% - 25% 22% Projected Year of Payment 2023 - 2025 2024 Revenue-based Payments $136 million Discounted Cash Flow Discount Rate 6 % - 14% 7% Probability of Payment 100% 100% Projected Year of Payment 2023 - 2024 2023 (1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average. Projected contingent payment amounts related to our R&D, regulatory and commercialization-based and revenue-based milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of December 31, 2022. Strategic Investments The aggregate carrying amount of our strategic investments was comprised of the following: As of December 31, (in millions) 2022 2021 Equity method investments $ 188 $ 259 Measurement alternative investments (1) 216 142 Publicly-held securities (2) 2 10 Notes receivable 1 — $ 407 $ 412 (1) Measurement alternative investments are privately-held equity securities or agreements for future equity without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying consolidated statements of operations. (2) Publicly-held equity securities are measured at fair value with changes in fair value recognized in Other, net within our consolidated statements of operations. These investments are classified as Other long-term assets within our consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In 2021, we recorded a $178 million loss on our investment in Pulmonx Corporation presented in Other, net

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows: As of December 31, 2022 As of December 31, 2021 (in millions) Gross Carrying Amount Accumulated Gross Carrying Amount Accumulated Technology-related $ 12,397 $ (7,378) $ 11,957 $ (6,754) Patents 486 (394) 494 (398) Other intangible assets 1,960 (1,400) 1,900 (1,325) Amortizable intangible assets $ 14,843 $ (9,173) $ 14,351 $ (8,476) Goodwill $ 22,820 $ (9,900) $ 21,888 $ (9,900) IPR&D 112 126 Technology-related 120 120 Indefinite-lived intangible assets $ 232 $ 246 The increase in our balance of goodwill and amortizable intangible assets is related primarily to our acquisition of Baylis Medical completed in the first quarter of 2022. Intangible asset impairment charges were $132 million in 2022, $370 million in 2021 and $460 million in 2020. The impairment charges recorded in 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which is now part of our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges. The impairment charges recorded in 2021 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of VENITI, Inc., which is now part of our Peripheral Interventions business. These charges resulted from management’s decision to discontinue commercialization of the VICI VENOUS STENT™ System following a voluntary recall, due to cost to remediate and time to return to market. In addition, during 2021, we impaired the IPR&D assets established in connection with our acquisition of Millipede, Inc. which is now part of our Cardiology business. The charges resulted from the cancellation of the mitral valve IPR&D program due to the incremental time and cost required to complete the program and bring the technology to market. The impairment charges recorded in 2020 were primarily associated with intangible assets established in connection with our acquisitions of Sadra Medical, Inc., Apama Medical Inc. and nVision Medical Corporation (nVision). Each of these impairment charges were recorded following management’s decision to cancel the programs due to the length of time, and remaining cost to complete and commercialize the technology, the cost to remediate quality issues or, specific to nVision, our understanding of the clinical evidence necessary to commercialize the technology. The following represents our goodwill balance by reportable segment. (in millions) MedSurg Cardiovascular Total Balance as of December 31, 2020 $ 3,707 $ 6,243 $ 9,951 Goodwill acquired 544 1,520 2,064 Foreign currency fluctuations and other changes (5) (21) (27) Balance as of December 31, 2021 $ 4,246 $ 7,741 $ 11,988 Goodwill acquired — 1,030 1,030 Foreign currency fluctuations and other changes (10) (88) (98) Balance as of December 31, 2022 $ 4,237 $ 8,684 $ 12,920 In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. We have revised prior periods to conform to the current year presentation. There was no impact to the reporting units identified for purposes of our annual goodwill impairment testing. In the second quarter of 2022, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. We determined that the fair value of each reporting unit exceeded its carrying value and concluded that goodwill was not impaired or at risk of impairment. Refer to Note A – Significant Accounting Policies for further discussion of our goodwill and intangible asset impairment testing. Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December 31, 2022 is as follows (in millions): Fiscal Year 2023 $ 781 2024 741 2025 683 2026 665 2027 625

Hedging Activities and Fair Val

Hedging Activities and Fair Value Measurements	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS	NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS Derivative Instruments and Hedging Activities We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item. We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency. Currency Hedging Instruments Risk Management Strategy Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; net investments in certain subsidiaries; and, during 2022 prior to our acquisition of M.I. Tech, the purchase price of M.I. Tech, which was denominated in a currency other than the U.S. dollar. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates. The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, British pound sterling, Swiss franc, Japanese yen, Chinese renminbi and Australian dollar. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows. Hedge Designations and Relationships Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815 , Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) within our consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within Cost of products sold in our consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within AOCI to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows. We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the Foreign currency translation adjustment (CTA) component of OCI , and we reclassify amortization of the excluded component from AOCI to current period earnings within Interest expense in our consolidated statements of operations. We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of December 31, 2022 and 2021, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in 2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the CTA component of OCI . We reclassify these gains and losses to current period earnings within Other, net in our consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary. We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net in our consolidated statements of operations. Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the KRW denominated purchase price of M.I. Tech. As of December 31, 2022, we had entered into $228 million in aggregate notional amount of these contracts. Interest Rate Hedging Instruments Risk Management Strategy Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815. Hedge Designations and Relationships We had no interest rate derivative instruments designated as cash flow hedges outstanding as of December 31, 2022 and December 31, 2021. In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs. The balance of the deferred amounts on our terminated cash flow hedges within AOCI was a $8 million loss as of December 31, 2022 and a $24 million loss as of December 31, 2021. We had no interest rate derivative instruments designated as fair value hedges outstanding as of December 31, 2022 and December 31, 2021. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in Interest expense , which generally offset. The following table presents the contractual amounts of our hedging instruments outstanding: (in millions) FASB ASC Topic 815 Designation As of December 31, 2022 2021 Forward currency contracts Cash flow hedge $ 2,725 $ 3,996 Forward currency contracts Net investment hedge 365 493 Foreign currency-denominated debt (1) Net investment hedge 997 997 Forward currency contracts Non-designated 4,235 3,892 Total Notional Outstanding $ 8,321 $ 9,378 (1) Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge. The remaining time to maturity as of December 31, 2022 is within 48 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature within the next year. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027. The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to Note O – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss). Effect of Hedging Relationships on Accumulated Other Comprehensive Income Amount Recognized in OCI on Hedges Consolidated Statements of Operations (1) Amount Reclassified from AOCI into Earnings (in millions) Pre-Tax Gain (Loss) Tax Benefit (Expense) Gain (Loss) Net of Tax Location of Amount Reclassified and Total Amount of Line Item Pre-Tax (Gain) Loss Tax (Benefit) Expense (Gain) Loss Net of Tax Year Ended December 31, 2022 Forward currency contracts Cash flow hedges $ 276 $ (62) $ 214 Cost of products sold $ 3,956 $ (209) $ 47 $ (162) Net investment hedges (2) 41 (10) 32 Interest expense 470 (10) 2 (8) Foreign currency-denominated debt Net investment hedges (3) 61 (14) 47 Other, net 38 — — — Interest rate derivative contracts Cash flow hedges — — — Interest expense 470 16 (4) 13 Year Ended December 31, 2021 Forward currency contracts Cash flow hedges $ 268 $ (60) $ 208 Cost of products sold $ 3,711 $ (54) $ 12 $ (42) Net investment hedges (2) 56 (13) 43 Interest expense 341 (13) 3 (10) Foreign currency-denominated debt Net investment hedges (3) 82 (19) 64 Other, net (218) — — — Interest rate derivative contracts Cash flow hedges — — — Interest expense 341 5 (1) 4 Year Ended December 31, 2020 Forward currency contracts Cash flow hedges $ (99) $ 22 $ (77) Cost of products sold $ 3,465 $ (83) $ 19 $ (64) Net investment hedges (2) (37) 8 (29) Interest expense 361 (24) 5 (19) Foreign currency-denominated debt Net investment hedges (3) (89) 21 (68) Other, net (362) — — — Interest rate derivative contracts Cash flow hedges — — — Interest expense 361 5 (1) 4 (1) In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings. (2) For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings. (3) For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI . No amounts were reclassified from AOCI to current period earnings. As of December 31, 2022, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions): Designated Hedging Instrument FASB ASC Topic 815 Designation Location on Consolidated Statements of Operations Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings Forward currency contracts Cash flow hedge Cost of products sold $ 223 Forward currency contracts Net investment hedge Interest expense 10 Interest rate derivative contracts Cash flow hedge Interest expense (3) Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below: (in millions) Location on Consolidated Statements of Operations Year Ended December 31, 2022 2021 2020 Net gain (loss) on currency hedge contracts Other, net $ (53) $ (16) $ 73 Net gain (loss) on currency transaction exposures Other, net 21 (12) (105) Net currency exchange gain (loss) $ (31) $ (27) $ (32) Fair Value Measurements FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures , and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities: (in millions) Location on Consolidated Balance Sheets (1) As of December 31, 2022 2021 Derivative and Nonderivative Assets: Designated Hedging Instruments Forward currency contracts Other current assets $ 196 $ 183 Forward currency contracts Other long-term assets 149 169 345 352 Non-Designated Hedging Instruments Forward currency contracts Other current assets 36 42 Total Derivative and Nonderivative Assets $ 381 $ 394 Derivative and Nonderivative Liabilities: Designated Hedging Instruments Forward currency contracts Other current liabilities $ — $ 32 Forward currency contracts Other long-term liabilities 1 6 Foreign currency-denominated debt (2) Other long-term liabilities 952 1,011 953 1,049 Non-Designated Hedging Instruments Forward currency contracts Other current liabilities 52 22 Total Derivative and Nonderivative Liabilities $ 1,005 $ 1,071 (1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less. (2) Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item. Recurring Fair Value Measurements On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows: • Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities. • Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs. • Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. Assets and liabilities measured at fair value on a recurring basis consist of the following: As of December 31, 2022 December 31, 2021 (in millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Money market funds and time deposits $ 673 $ — $ — $ 673 $ 1,632 $ — $ — $ 1,632 Publicly-held securities 2 — — 2 10 — — 10 Hedging instruments — 381 — 381 — 394 — 394 Licensing arrangements — — 127 127 — — 246 246 $ 674 $ 381 $ 127 $ 1,182 $ 1,642 $ 394 $ 246 $ 2,282 Liabilities Hedging instruments $ — $ 1,005 $ — $ 1,005 $ — $ 1,071 $ — $ 1,071 Contingent consideration liability — — 149 149 — — 486 486 Licensing arrangements — — 159 159 — — 281 281 $ — $ 1,005 $ 308 $ 1,313 $ — $ 1,071 $ 767 $ 1,838 Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents within our accompanying consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $673 million invested in money market funds and time deposits as of December 31, 2022 and $1.632 billion as of December 31, 2021, we held $256 million in interest-bearing and non-interest-bearing bank accounts as of December 31, 2022 and $293 million as of December 31, 2021. Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability. In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We own the contractual right to receive 50 percent of the future Zytiga™ Drug royalty payments from the licensee and remit such payments to the inventors associated with the intellectual property. We recognized a financial asset and associated liability for our licensing arrangements at fair value in our consolidated balance sheets using the fair value option in accordance with FASB ASC Topic 825, Financial Instruments. We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these instruments. Royalty payments we receive reduce the fair value of the financial asset and are presented within Proceeds from royalty rights, and payments we remit to inventors reduce the fair value of the financial liability and are presented within Payments for royalty rights within our consolidated statements of cash flows. We sold our right to receive and retain the other 50 percent of the future royalty payments in 2019 for an upfront cash payment, which we accounted for as a secured borrowing in accordance with FASB ASC Topic 860, Transfers and Servicing . Although we sold these rights, we continue to recognize at fair value the future royalty payments as a financial asset and associated liability. Royalty payments associated with the rights we sold no longer impact our cash flows, and we present this activity as Non-cash impact of transferred royalty rights in the supplemental information to our consolidated statements of cash flows. We reduce the fair value of the financial asset and associated liability when such non-cash activity occurs. We record the fair value of the financial asset and associated liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of December 31, 2022. However, increases or decreases in the financial asset would be offset by increases or decreases in the financial liability, other than for timing of receipt and remittance; as such our earnings are not subject to material gains and losses from the licensing arrangement. The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2022 include the following significant unobservable inputs: Licensing Arrangements Fair Value as of December 31, 2022 Valuation Technique Unobservable Input Range Weighted Average (1) Financial Asset $127 million Discounted Cash Flow Discount Rate 15% 15% Projected Year of Payment 2023 - 2025 2024 Financial Liability $159 million Discounted Cash Flow Discount Rate 12% - 15% 13% Projected Year of Payment 2023 - 2026 2024 (1) Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average. Changes in the fair value of our licensing arrangements' financial asset were as follows: (in millions) Balance as of December 31, 2020 $ 365 Proceeds from royalty rights (163) Fair value adjustment (expense) benefit 44 Balance as of December 31, 2021 $ 246 Proceeds from royalty rights (141) Fair value adjustment (expense) benefit 22 Balance as of December 31, 2022 $ 127 Changes in the fair value of our licensing arrangements' financial liability were as follows: (in millions) Balance as of December 31, 2020 $ 407 Payments for royalty rights (166) Fair value adjustment expense (benefit) 41 Balance as of December 31, 2021 $ 281 Payments for royalty rights (145) Fair value adjustment expense (benefit) 23 Balance as of December 31, 2022 $ 159 Non-Recurring Fair Value Measurements We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C – Goodwill and Other Intangible Assets for a discussion of the fair values of our intangible assets including goodwill. The fair value of our outstanding debt obligations was $8.203 billion as of December 31, 2022 and $10.196 billion as of December 31, 2021. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.

Contractual Obligations and Com

Contractual Obligations and Commitments	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
CONTRACTUAL OBLIGATIONS AND COMMITMENTS	NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS Borrowings and Credit Arrangements We had total debt outstanding of $8.935 billion as of December 31, 2022 and $9.065 billion as of December 31, 2021, with current maturities of $20 million as of December 31, 2022 and $261 million as of December 31, 2021. The debt maturity schedule for our long-term debt obligations is presented below: Issuance Date Maturity Date As of December 31, Coupon Rate (1) (in millions, except interest rates) 2022 2021 October 2023 Senior Notes (4) August 2013 October 2023 $ — $ 244 4.125% March 2024 Notes (4) February 2019 March 2024 504 850 3.450% March 2025 Senior Notes (3) March 2022 March 2025 1,067 — 0.750% May 2025 Senior Notes (4) May 2015 May 2025 — 523 3.850% June 2025 Senior Notes May 2020 June 2025 500 500 1.900% March 2026 Senior Notes (4) February 2019 March 2026 255 850 3.750% December 2027 Senior Notes (3) November 2019 December 2027 960 1,021 0.625% March 2028 Senior Notes (3) March 2022 March 2028 800 — 1.375% March 2028 Senior Notes (4) February 2018 March 2028 344 434 4.000% March 2029 Senior Notes (4) February 2019 March 2029 272 850 4.000% June 2030 Senior Notes May 2020 June 2030 1,200 1,200 2.650% March 2031 Senior Notes (3) March 2022 March 2031 800 — 1.625% March 2034 Senior Notes (3) March 2022 March 2034 534 — 1.875% November 2035 Senior Notes (2) November 2005 November 2035 350 350 6.750% March 2039 Senior Notes (4) February 2019 March 2039 450 750 4.550% January 2040 Senior Notes December 2009 January 2040 300 300 7.375% March 2049 Senior Notes (4) February 2019 March 2049 650 1,000 4.700% Unamortized Debt Issuance Discount and Deferred Financing Costs 2023 - 2049 (76) (76) Unamortized Gain on Fair Value Hedges 2022 — 3 Finance Lease Obligation Various 5 6 Long-term debt $ 8,915 $ 8,804 Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges. (1) Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon. (2) Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective November 15, 2021, the interest rate payable decreased by 0.25 percent and began accruing at a rate of 6.75 percent following upgrades to our credit ratings. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings. (3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December 31, 2022 and 2021, respectively. (4) Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. In addition, in the first quarter of 2022, we repaid $250 million of 3.375% May 2022 Senior Notes classified within Current Debt Obligations within our consolidated balance sheets as of December 31, 2021. Contractual maturities of our long-term debt outstanding as of December 31, 2022 are as follows: Fiscal Year 2023 $ — 2024 504 2025 1,567 2026 255 2027 960 Thereafter 5,700 Revolving Credit Facility On May 10, 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks and terminated our previous facility (2018 Revolving Credit Facility). The 2021 Revolving Credit Facility will mature on May 10, 2026, with one-year extension options, subject to certain conditions. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the Revolving Credit Facility as of December 31, 2022 or December 31, 2021. Financial Covenant As of December 31, 2022, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility. Covenant Requirement Actual Maximum permitted leverage ratio (1) 3.75 times 2.57 times (1) Ratio of total debt to deemed consolidated EBITDA, as defined by the credit agreements, as amended. The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for qualified acquisitions due to our funding of these acquisitions using cash on hand. The financial covenant requirement provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of December 31, 2022, we had $265 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreements, are excluded from the calculation of consolidated EBITDA, as defined by the agreements, provided that the sum of any excluded net cash litigation payments do not exceed $1.455 billion in the aggregate. As of December 31, 2022, we had $866 million of the litigation exclusion remaining. Any inability to maintain compliance with this covenant could require us to seek to further renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable . Commercial Paper Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December 31, 2022 and 2021. Senior Notes We had senior notes outstanding of $8.986 billion as of December 31, 2022 and $9.121 billion as of December 31, 2021. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see Other Arrangements below). In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes comprised of €1.000 billion of 0.750% Senior Notes due 2025, €750 million of 1.375% Senior Notes due 2028, €750 million of 1.625% Senior Notes due 2031 and €500 million of 1.875% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs. We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment charges of $194 million during the first quarter of 2022 presented in Interest expense within our consolidated statements of operations. Other Arrangements We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, Transfers and Servicing . We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions): As of December 31, 2022 As of December 31, 2021 Factoring Arrangements Amount Weighted Average Interest Rate Amount Weighted Average Interest Rate Euro denominated $ 161 2.4 % $ 141 2.1 % Yen denominated 194 0.6 % 223 0.6 % Renminbi denominated 13 3.1 % 11 3.2 % Other Contractual Obligations and Commitments We had outstanding letters of credit of $135 million as of December 31, 2022 and $134 million as of December 31, 2021, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of December 31, 2022 and December 31, 2021, we had not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets. Future minimum purchase obligations, relating primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business, were as of December 31, 2022 (in millions): Fiscal Year Unrecorded Purchase Obligations 2023 $ 755 2024 119 2025 71 2026 35 2027 19 Thereafter 21 $ 1,021

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Lessee, Operating Leases	NOTE F – LEASES We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term and, as a result, the remaining lease term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. In accordance with FASB ASC Topic 842, Leases , we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than 1 year to approximately 54 years, some of which may include options to extend the leases for up to 10 years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term. We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. Our operating lease right-of-use assets are presented within Other long-term assets and corresponding liabilities are presented within Other current liabilities and Other long-term liabilities on our consolidated balance sheets. Refer to Note E – Contractual Obligations and Commitments for information regarding our finance leases. The following table presents supplemental balance sheet information related to our operating leases: As of December 31, (in millions) 2022 2021 Assets Operating lease right-of-use assets in Other long-term assets $ 386 $ 435 Liabilities Operating lease liabilities in Other current liabilities 61 71 Operating lease liabilities in Other long-term liabilities 347 389 The following table presents the weighted average remaining lease term and discount rate information related to our operating leases: As of December 31, 2022 2021 Weighted average remaining lease term 10 years 10 years Weighted average discount rate 3.3% 2.6% Our operating lease cost under FASB ASC Topic 842 was $91 million in 2022, $90 million in 2021 and $92 million in 2020. The following table presents supplemental cash flow information related to our operating leases: Year Ended December 31, (in millions) 2022 2021 Cash paid for amounts included in the measurement of operating lease liabilities Operating cash flows from operating leases $ 91 $ 87 Right-of-use assets obtained in exchange for operating lease obligations were $43 million and $68 million for the years ended December 31, 2022 and 2021. The following table presents the maturities of our operating lease liabilities as of December 31, 2022 (in millions): Fiscal year Operating Leases 2023 $ 80 2024 66 2025 55 2026 43 2027 34 Thereafter 214 Total future minimum operating lease payments 492 Less: imputed interest (84) Present value of operating lease liabilities $ 408

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	12 Months Ended
	Dec. 31, 2022
Supplemental Balance Sheet Information [Abstract]
SUPPLEMENTAL BALANCE SHEET INFORMATION	NOTE G – SUPPLEMENTAL BALANCE SHEET INFORMATION Components of selected captions in our accompanying consolidated balance sheets are as follows: Trade accounts receivable, net As of December 31, (in millions) 2022 2021 Trade accounts receivable $ 2,079 $ 1,886 Allowance for credit losses (109) (108) $ 1,970 $ 1,778 The following is a rollforward of our Allowance for credit losses : Year Ended December 31, (in millions) 2022 2021 2020 Beginning balance $ 108 $ 105 $ 74 Cumulative effect adjustment for adoption of ASU 2016-13 n/a n/a 10 Credit loss expense 35 28 49 Write-offs (35) (25) (27) Ending balance $ 109 $ 108 $ 105 Note: Effective January 1, 2020, we adopted FASB ASC Topic 326 using the modified retrospective method, which requires that we recognize credit loss reserves when financial assets are established if credit losses are expected over the asset’s contractual life. Inventories As of December 31, (in millions) 2022 2021 Finished goods $ 1,171 $ 1,029 Work-in-process 147 128 Raw materials 548 452 $ 1,867 $ 1,610 Approximately 27 percent of our finished goods inventory as of December 31, 2022 and approximately 30 percent as of December 31, 2021 was at customer locations pursuant to consignment arrangements or held by sales representatives. Other current assets As of December 31, (in millions) 2022 2021 Restricted cash and restricted cash equivalents $ 149 $ 188 Derivative assets 232 226 Licensing arrangements 60 132 Other 290 254 $ 731 $ 799 Property, plant and equipment, net As of December 31, (in millions) 2022 2021 Land $ 137 $ 109 Buildings and improvements 1,695 1,523 Equipment, furniture and fixtures 3,297 3,287 Capital in progress 598 605 5,728 5,525 Less: accumulated depreciation 3,282 3,273 $ 2,446 $ 2,252 Depreciation expense was $333 million in 2022, $352 million in 2021 and $333 million in 2020. Other long-term assets As of December 31, (in millions) 2022 2021 Restricted cash equivalents $ 48 $ 55 Operating lease right-of-use assets 386 435 Derivative assets 149 169 Investments 407 412 Licensing arrangements 67 114 Indemnification asset 172 — Other 271 225 $ 1,500 $ 1,410 Accrued expenses As of December 31, (in millions) 2022 2021 Legal reserves $ 231 $ 264 Payroll and related liabilities 830 848 Rebates 352 350 Contingent consideration 74 289 Other 674 686 $ 2,160 $ 2,436 Other current liabilities As of December 31, (in millions) 2022 2021 Deferred revenue $ 220 $ 208 Licensing arrangements 79 138 Taxes payable 232 209 Other 230 228 $ 761 $ 783 Other long-term liabilities As of December 31, (in millions) 2022 2021 Accrued income taxes $ 597 $ 442 Legal reserves 212 284 Contingent consideration 75 197 Licensing arrangements 80 143 Operating lease liabilities 347 389 Deferred revenue 289 276 Other 434 489 $ 2,035 $ 2,220

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE H – INCOME TAXES Our Income (loss) before income taxes consisted of the following: Year Ended December 31, (in millions) 2022 2021 2020 Domestic $ (1,119) $ (648) $ (660) Foreign 2,260 1,724 581 $ 1,141 $ 1,076 $ (79) The related expense (benefit) for income taxes consisted of the following: Year Ended December 31, (in millions) 2022 2021 2020 Current Federal $ 51 $ 18 $ (29) State 19 33 (35) Foreign 381 127 151 451 178 87 Deferred Federal (92) (256) (26) State (32) (3) (6) Foreign 117 117 (53) (7) (142) (85) $ 443 $ 36 $ 2 The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows: Year Ended December 31, 2022 2021 2020 U.S. federal statutory income tax rate 21.0 % 21.0 % (21.0) % State income taxes, net of federal benefit 0.7 % 2.5 % 16.6 % Domestic taxes on foreign earnings 15.3 % 6.8 % 155.4 % Effect of foreign taxes (3.8) % (14.3) % (40.7) % Acquisition-related 4.4 % (8.1) % (16.7) % Research credit (4.5) % (3.0) % (43.0) % Valuation allowance (1.3) % 0.8 % (42.0) % Goodwill impairment charges — % — % 3.7 % Compensation-related 0.6 % (0.6) % (7.7) % Non-deductible expenses 0.4 % 0.4 % 64.4 % Uncertain tax positions 7.7 % 1.2 % (96.8) % Intra-entity asset transfers — % — % 10.2 % Return to provision (2.1) % (5.7) % (37.3) % Change in tax rates (0.2) % 1.9 % 51.8 % Other, net 0.7 % 0.4 % 6.0 % 38.9 % 3.3 % 2.9 % Significant components of our deferred tax assets and liabilities are as follows: As of December 31, (in millions) 2022 2021 Deferred Tax Assets: Inventory costs and related reserves $ 19 $ 10 Tax benefit of net operating losses and credits 511 620 Reserves and accruals 304 324 Restructuring-related charges 6 14 Litigation and product liability reserves 103 127 Investment write-down 38 31 Compensation related 136 130 Federal benefit of uncertain tax positions 9 8 Intangible assets 3,668 3,546 Capitalized R&D 160 67 Property, plant and equipment 2 14 Other — 35 4,954 4,926 Less: valuation allowance (1,004) (1,014) 3,950 3,912 Deferred Tax Liabilities: Unrealized gains and losses on derivative financial instruments 117 79 Other 34 — 151 79 Net Deferred Tax Assets 3,799 3,833 Prepaid on intercompany profit 264 205 Net Deferred Tax Assets and Prepaid on Intercompany Profit $ 4,062 $ 4,038 Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions): Location on Consolidated Balance Sheets As of December 31, Component 2022 2021 Prepaid on intercompany profit Prepaid income taxes $ 264 $ 205 Non-current deferred tax asset Deferred tax assets 3,942 4,142 Deferred Tax Assets and Prepaid on Intercompany Profit 4,206 4,348 Non-current deferred tax liability Deferred tax liabilities 144 310 Deferred Tax Liabilities 144 310 Net Deferred Tax Assets and Prepaid on Intercompany Profit $ 4,062 $ 4,038 As of December 31, 2022, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $464 million. As of December 31, 2021, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $560 million. In addition, we had foreign tax net operating loss carryforwards and tax credits, the tax effect of which was $47 million as of December 31, 2022, and $60 million as of December 31, 2021. These tax attributes expire periodically beginning in 2023. After consideration of all positive and negative evidence, we believe that it is more likely than not that a portion of our deferred tax assets will not be realized. As a result, we recorded a valuation allowance of $1.004 billion as of December 31, 2022, and $1.014 billion as of December 31, 2021. The decrease in the valuation allowance as of December 31, 2022, compared to December 31, 2021, is primarily due to the release of valuation allowances on certain U.S. state net operating losses and tax credit carryforwards due to the repatriation of foreign earnings, offset by the concurrent build of the valuation allowance on other state attributes. The income tax impact of the unrealized gain or loss component of other comprehensive income and stockholders' equity was a charge of $56 million in 2022, a charge of $81 million in 2021 and a benefit of $78 million in 2020. We obtain tax incentives through Free Trade Zone Regime offered in Costa Rica which allows 100 percent exemption from income tax in the first eight years of operations and 50 percent exemption in the following four years. This tax incentive resulted in income tax savings of $162 million in 2022, $149 million in 2021 and $64 million in 2020. The tax incentive for 100 percent exemption from income tax is expected to expire in 2027, with the 50 percent exemption to expire in 2031. The impact on Net income (loss) per common share - assuming dilution was $0.11 for 2022, $0.10 for 2021 and $0.04 for 2020. We also benefit from tax incentives in Puerto Rico through a Grant of Industrial Tax Exemption (Grant) which applies a reduced tax rate to our taxable profits, resulting in income tax savings of $21 million in 2022, $27 million in 2021 and $30 million in 2020. This Grant expires in 2034, with an option to extend for an additional 15 years. The impact on Net income (loss) per common share - assuming dilution was $0.02 in each of the years 2022, 2021 and 2020. Additionally, we benefit from tax incentives in Malaysia which allow a full tax exemption on manufacturing of specific medical device products, which will expire in 2029, with an option to renew for an additional five-year term. This incentive has resulted in income tax savings of $17 million in 2022 and $0 in 2021 and 2020. The impact on Net income (loss) per common share - assuming dilution was $0.01 in 2022 and de minimis in 2021 and 2020. As of December 31, 2022, we had $492 million of gross unrecognized tax benefits, of which a net $410 million, if recognized, would affect our effective tax rate. As of December 31, 2021, we had $255 million of gross unrecognized tax benefits, of which a net $177 million, if recognized, would affect our effective tax rate. As of December 31, 2020, we had $261 million of gross unrecognized tax benefits, of which a net $183 million, if recognized, would affect our effective tax rate. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended December 31, (in millions) 2022 2021 2020 Beginning Balance $ 255 $ 261 $ 455 Additions based on positions related to the current year 88 8 28 Additions based on positions related to prior years 177 41 6 Reductions for tax positions of prior years (20) (36) (186) Settlements with taxing authorities (1) (2) (27) Statute of limitation expirations (8) (17) (15) Ending Balance $ 492 $ 255 $ 261 We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal income tax matters through 2016 and substantially all material state and local income tax matters through 2014. We have concluded substantially all foreign income tax matters through 2015. In 2020, we received notification from the IRS regarding the examination of our 2014 through 2016 tax years stating that the Joint Committee on Taxation completed its review, and the IRS examination was resolved. Due to the resolution of these tax years, we recorded a net tax benefit of $91 million to release the reserves related to these years. We received a refund of $62 million from the IRS reflecting the net balance of amounts owed to us by the IRS after consideration of tax and interest due for these years. We recognize interest and penalties related to income taxes as a component of income tax expense. We had $77 million accrued for gross interest and penalties as of December 31, 2022, $43 million as of December 31, 2021, and $41 million as of December 31, 2020. Net tax expense related to interest and penalties was immaterial in 2022, 2021 and 2020. The increase in our net tax expense related to interest and penalties as of December 31, 2022, compared to December 31, 2021, is related to reaching settlements with taxing authorities. It is reasonably possible that within the next 12 months we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $75 million. For the year ended December 31, 2017, we were required under the TCJA to calculate a one-time transition tax based on our total post-1986 foreign subsidiaries' earnings and profits (E&P) that we previously deferred from U.S. income taxes. As a result of various audit activities, the revised amount of transition tax was approximately $937 million as of December 31, 2022, as compared to $938 million as of December 31, 2021. We anticipate offsetting this liability against existing tax attributes, reducing the required payment to approximately $586 million, which will be remitted over an eight-year period. We have begun

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE I – COMMITMENTS AND CONTINGENCIES The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies. During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity. In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity. In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity. In accordance with FASB ASC Topic 450, Contingencies , we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. Our accrual for legal matters that are probable and estimable was $443 million as of December 31, 2022, and $548 million as of December 31, 2021, and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of our legal accrual for transvaginal surgical mesh product claims is already funded through our qualified settlement fund (QSF), which is included in restricted cash and restricted cash equivalents in Other current assets of $149 million as of December 31, 2022, and $188 million as of December 31, 2021. Refer to Note A – Significant Accounting Policies for additional information. We recorded litigation-related net charges of $173 million in 2022, $430 million in 2021 and $278 million in 2020, primarily related to ongoing litigation associated with our transvaginal surgical mesh products principally in the U.S. and Australia, as well as costs associated with certain other legal matters. We increased the accrual associated with transvaginal mesh claims to account for changes in our estimates regarding settlement and litigation activity. The charges recorded in 2020 were also inclusive of a reserve related to claims made by a coalition of state attorneys general, which has since been settled. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant. In management's opinion, we are not currently involved in any legal proceedings other than those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated. Patent Litigation On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct™ Endoscopic Hemoclip. The Company seeks lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed Inter Partes Review (IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the court staying the case until 2020. All IPRs concluded and confirmed the validity of certain claims of each challenged patent. In February 2023, the District Court issued summary judgment rulings dismissing certain claims and defenses. Trial on the remaining two asserted patents is scheduled for May 2023. The Company has also asserted patents against Cook in Germany and the United Kingdom. Trials are scheduled in the United Kingdom in February 2023 and in Germany in April 2023. On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against us in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. The Company intends to appeal the jury's verdict. Product Liability Litigation Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements in principle or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand. We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. While our U.S. case count has remained materially the same over the past three years, we have increased our reserve to account for changes in our estimates regarding settlement and litigation activity. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims. We continue to vigorously contest these cases and claims and expect that more cases will go to trial in the coming years than have gone to trial in the past several years. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products. Governmental Investigations and Qui Tam Matters On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision. In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations. Other Proceedings On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Mariano Errichiello as the lead plaintiff. Under the terms of the Court-approved Scheduling Order, Counsel for Mr. Errichiello was required to file an Amended Complaint on or before June 4, 2021, which they did. The Amended Complaint seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. In response, the Company brought a Motion to Dismiss the Amended Complaint which it filed on July 19, 2021. On December 20, 2022, the Court granted in part and denied in part the Company’s motion to dismiss. The Company intends to vigorously defend itself against the surviving allegations. On December 15, 2020, the Securities and Exchange Commission’s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company’s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action. On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund and Diane Nachbaur, two stockholders of the Company, on July 26, 2021, and July 29, 2021, respectively, each demanding access to certain books and records of the Company, pursuant to 8 Delaware Section 220, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items. Matters Concluded Since December 31, 2021 On December 21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research & Development, LLC, and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint filed on behalf of the United States, 29 states, and the District of Columbia. The complaint, which was filed in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of New Jersey. On June 20, 2019, the complaint was amended to include BTG International Limited as a defendant. In May 2020, a class action complaint was filed in New Jersey federal court against Janssen and BTG by a direct purchaser of Zytiga on behalf of similarly situated entities. The complaint was amended in February 2021 and alleged that BTG and Janssen violated antitrust laws by attempting to enforce certain patents against potential generic competitors. On October 12, 2021, the court granted BTG and Janssen’s motion to compel arbitration in the direct purchaser action and stayed all direct purchaser proceedings. On December 17, 2021, the court granted BTG’s motion to dismiss the qui tam action. On January 10, 2022, the court granted the parties’ stipulation of dismissal with prejudice as to the claims of the direct purchaser plaintiff, whose claims had been stayed in the October 12, 2021, order compelling arbitration. On May 16, 2018, Arthur Rosenthal et al., filed a plenary summons against Boston Scientific Corporation and Boston Scientific Limited with the High Court of Ireland alleging that payments were due pursuant a transaction agreement regarding Labcoat Limited, a company Boston Scientific purchased in 2008 that provided coating technology for drug-eluting stents. Labcoat sought monetary damages related to an earn-out provision. On March 25, 2022, the parties agreed to a confidential settlement which resolved the dispute. The settlement did not have a material impact on our financial position or results of operations. On December 9, 2016, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement action against Nevro Corp. (Nevro) in United States District Court for the District of Delaware (16-cv-1163) alleging that ten U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro's Senza™ Spinal Cord Stimulation (SCS) System. The Company sought lost profits, a reasonable royalty and a permanent injunction. At a trial held in October and November 2021 regarding six of Boston Scientific's originally asserted patent claims, a jury granted Boston Scientific a monetary award, finding that each asserted claim was valid, that four of the six claims were infringed by Nevro, and that two of the claims were willfully infringed by Nevro. On July 29, 2022, the parties reached a confidential settlement agreement, pursuant to which the Company agreed to make a payment to Nevro of $85 million to resolve all pending litigation between the parties, including this matter and the 18-cv-664 and 21-cv-258 matters described below. On April 21, 2018, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement, theft of trade secrets and tortious interference with a contract action against Nevro in United States District Court for the District of Delaware (18-cv-664), and amended the complaint on July 18, 2018, alleging that nine U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro’s Senza™ I and Senza™ II SCS Systems. On December 9, 2019, Nevro filed an answer and counterclaims, in which it alleged that our SCS systems infringed five Nevro patents. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above. On February 23, 2021, Nevro filed a complaint against the Company in the United States District Court for the District of Delaware (21-cv-258). The complaint alleged infringement of five Nevro patents by certain of the Company’s spinal cord stimulation systems. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
STOCKHOLDER'S EQUITY	NOTE J – STOCKHOLDERS' EQUITY Preferred Stock We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders. On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock (MCPS), Series A at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2022, our MCPS had an aggregate liquidation preference of $1.006 billion. Holders of MCPS will be entitled to receive, when, as and if declared by our Board of Directors, or an authorized committee thereof, out of funds legally available for payment, cumulative dividends at the annual rate of 5.50% of the liquidation preference of $100 per share, payable in cash or, subject to certain limitations, by delivery of shares of common stock or any combination of cash and shares of common stock, at our election; provided, however, that any unpaid dividends on the MCPS will continue to accumulate as described in the Certificate of Designations. Subject to certain exceptions, no dividend or distribution will be declared or paid on shares of our common stock, and no common stock will be purchased, redeemed or otherwise acquired for consideration by us or any of our subsidiaries unless, in each case, all accumulated and unpaid dividends for all preceding dividend periods have been declared and paid, or a sufficient amount of cash or number of shares of common stock has been set apart for the payment of such dividends, on all outstanding shares of MCPS. In the event of our voluntary or involuntary liquidation, winding-up or dissolution, no distribution of our assets may be made to holders of our common stock until we have paid holders of our MCPS, each of which will be entitled to receive a liquidation preference in the amount of $100 per share plus accumulated and unpaid dividends. Unless earlier converted, each share of MCPS will automatically convert on June 1, 2023, subject to postponement for certain market disruption events, into between 2.3834 and 2.9197 shares of common stock, subject to customary anti-dilution adjustments. The number of shares of common stock issuable upon conversion will be determined based on the average volume-weighted average price per share of common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately preceding June 1, 2023. The MCPS is not subject to any redemption, sinking fund or other similar provisions. However, at our option, we may purchase or exchange the MCPS from time to time in the open market, by tender or exchange offer or otherwise, without the consent of, or notice to, holders of MCPS. The holders of the MCPS will not have any voting rights, with limited exceptions. During 2022, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared and we paid quarterly cash dividends of $14 million, or $1.3750 per MCPS share to holders, representing dividend periods through November 2022. On January 30, 2023, the Committee declared a cash dividend of $1.3750 per MCPS share to holders of our MCPS as of February 15, 2023, representing a dividend period from December 2022 through February 2023. We have presented cumulative, unpaid dividends within Accrued expenses within our consolidated balance sheets as of December 31, 2022. Common Stock We are authorized to issue 2.000 billion shares of common stock, $0.01 par value per share. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors, and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption, or conversion rights. The holders of common stock do not have cumulative voting rights. The holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairs. Holders of common stock are junior to holders of MCPS in terms of liquidation preference. On May 27, 2020, we completed an offering of 29,382,500 shares of common stock at a public offering price of $34.25 per share. The net proceeds from the common stock offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. We used a portion of the net proceeds from the May 27, 2020 MCPS and common stock offerings to repay remaining amounts outstanding under our previous term loan credit agreement that matured on April 20, 2021 and to pay related fees, expenses and premiums. The remaining proceeds were used for general corporate purposes. In 2020, we repurchased approximately 15.7 million shares of our common stock pursuant to our 2013 share repurchase program for a total of approximately $535 million in cash, which represented the full amount remaining under the existing authorization. On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. We did not repurchase any shares of our common stock during 2022 and had the full amount available under the authorization as of December 31, 2022. There were approximately 263 million shares in treasury as of December 31, 2022 and 2021.

Stock Inventive and Purchase Pl

Stock Inventive and Purchase Plans	12 Months Ended
	Dec. 31, 2022
Stock Incentive and Purchase Plans [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE K – STOCK INCENTIVE AND PURCHASE PLANS Employee and Director Stock Incentive Plans In 2020, our Board of Directors and stockholders approved amendments to our 2011 Long-Term Incentive Plan effective October 1, 2020 (Amended and Restated 2011 LTIP), authorizing for issuance up to 171 million shares of our common stock. The Amended and Restated 2011 LTIP covers officers, directors, employees and consultants and provides for the grant of restricted or unrestricted common stock, restricted stock units (RSUs), options to acquire our common stock, stock appreciation rights, performance awards (market-based and performance-based RSUs) and other stock and non-stock awards. Shares reserved under our current and former stock incentive plans totaled approximately 175 million as of December 31, 2022. The Executive Compensation and Human Resources Committee (the Committee) of the Board of Directors, consisting of independent, non-employee directors may authorize the issuance of common stock and cash awards under the Amended and Restated 2011 LTIP in recognition of the achievement of long-term performance objectives established by the Committee. Non-qualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date, vest over a four-year service period and have a ten-year contractual life. In the case of qualified options, if the recipient owns more than ten percent of the voting power of all classes of stock, the option granted will be at an exercise price of 110 percent of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years. Non-vested stock awards, including restricted stock awards (RSAs), RSUs and deferred stock units (DSUs) issued to employees are generally granted with an exercise price of zero and typically vest in four or five equal annual installments. These awards represent our commitment to issue shares to recipients after the vesting period. Upon each vesting date, such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient. The following presents the impact of stock-based compensation on our consolidated statements of operations: Year Ended December 31, (in millions, except per share data) 2022 2021 2020 Cost of products sold $ 12 $ 11 $ 9 Selling, general and administrative expenses 167 147 130 Research and development expenses 41 36 30 220 194 170 Income tax (benefit) expense (32) (29) (28) $ 188 $ 165 $ 142 Net impact per common share - basic $ 0.13 $ 0.12 $ 0.10 Net impact per common share - assuming dilution $ 0.13 $ 0.12 $ 0.10 Stock Options We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions: Year Ended December 31, 2022 2021 2020 Options granted (in thousands) 3,287 3,822 3,819 Weighted-average exercise price $ 44.02 $ 37.69 $ 41.79 Weighted-average grant-date fair value $ 13.64 $ 10.77 $ 10.44 Black-Scholes Assumptions Expected volatility 28 % 29 % 23 % Expected term (in years, weighted) 6.1 5.9 5.8 Risk-free interest rate 1.42% - 3.87% 0.66% - 1.20% 0.27% - 1.72% Expected Volatility We use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options. Expected Term We estimate the expected term of options using historical exercise and forfeiture data. We believe that this historical data provides the best estimate of the expected term of new option grants. Risk-Free Interest Rate We use yield rates on U.S. Treasury securities for a period approximating the expected term of the award to estimate the risk-free interest rate in our grant-date fair value assessment. Expected Dividend Yield We have not historically paid cash dividends on our common stock and currently we do not intend to pay cash dividends on our common stock. Therefore, we have assumed an expected dividend yield of zero in our grant-date fair value assessment. Information related to stock options under stock incentive plans are as follows: Stock Options (in thousands) Weighted Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (in millions) Outstanding as of December 31, 2019 23,065 $ 19 Granted 3,819 42 Exercised (3,096) 13 Cancelled/forfeited (666) 27 Outstanding as of December 31, 2020 23,122 $ 24 Granted 3,822 38 Exercised (4,796) 13 Cancelled/forfeited (699) 26 Outstanding as of December 31, 2021 21,448 $ 29 Granted 3,287 44 Exercised (2,745) 17 Cancelled/forfeited (502) 34 Outstanding as of December 31, 2022 21,489 $ 32 5.9 297 Exercisable as of December 31, 2022 13,674 27 4.6 258 Expected to vest as of December 31, 2022 7,535 41 8.2 38 Total vested and expected to vest as of December 31, 2022 21,209 $ 32 5.9 $ 296 The total intrinsic value of stock options exercised was $72 million in 2022, $137 million in 2021 and $84 million in 2020. Non-Vested Stock We value RSAs, RSUs and DSUs based on the closing trading value of our shares on the date of grant. Information related to non-vested stock awards is as follows: Non-Vested Stock Award Units (in thousands) Weighted Average Balance as of December 31, 2019 11,079 $ 29 Granted 3,609 41 Vested (1) (4,147) 25 Forfeited (554) 34 Balance as of December 31, 2020 9,987 $ 34 Granted 4,240 $ 39 Vested (1) (3,823) $ 31 Forfeited (658) 36 Balance as of December 31, 2021 9,745 $ 37 Granted 3,854 $ 45 Vested (1) (3,482) $ 36 Forfeited (680) 44 Balance as of December 31, 2022 9,438 $ 41 (1) The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements. The total vesting date fair value of shares that vested was approximately $150 million in 2022, $148 million in 2021 and $172 million in 2020. Market-based RSU and DSU Awards During 2022 and 2021, we granted market-based RSU awards, and in 2020, we granted market-based DSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&P 500 Healthcare Index over a three-year performance period. The number of RSUs and DSUs ultimately granted under this program range from 0 percent to 200 percent of the target number awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout the three-year performance period to attain the full amount of the market-based RSU's and DSUs that satisfied the market performance criteria. We determined the fair value of the market-based RSU and DSU awards to be approximately $12 million for 2022, $11 million for 2021 and $8 million for 2020. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions: 2022 2021 2020 Awards Awards Awards Stock price on date of grant $ 44.19 $ 37.50 $ 42.16 Measurement period (in years) 2.9 2.9 2.9 Risk-free rate 1.71 % 0.20 % 1.37 % We recognize the expense on these awards in our consolidated statements of operations on a straight-line basis over the three-year measurement period. Free Cash Flow Performance-based RSU and DSU Awards During 2022 and 2021, we granted free-cash flow performance-based RSU awards, and in 2020, we granted free-cash flow performance-based DSU awards to certain members of our senior management team. The attainment of these performance-based RSUs and DSUs is based on our adjusted free cash flow (AFCF) measured against our goal set by the Executive Compensation and Human Resources Committees of our Board of Directors, based on our internal annual financial plan performance for AFCF. AFCF is measured over a one-year performance period beginning January 1st of each year and ending December 31st. The number of RSUs and DSUs ultimately granted under this program range from 0 percent to 150 percent of the target number of performance-based RSUs and DSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout a three-year service period (inclusive of the one-year performance period) to attain the full amount of the performance-based RSUs and DSUs that satisfied the performance criteria. The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December 31, 2022: 2022 AFCF 2021 AFCF 2020 AFCF Fair value, net of forfeitures to date (in millions) $ 7 $ 12 $ 6 Achievement of target payout 88 % 131 % 89 % Year-end stock price used in determining fair value $ 46.27 $ 42.48 $ 35.95 We recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grant. Expense Attribution We recognize compensation expense for our stock incentive plan using a straight-line method over the substantive vesting period. Most of our stock awards provide for immediate vesting upon death or disability of the participant. In addition, our stock grants to employees provide for accelerated vesting of our stock-based awards, other than performance-based and market-based awards, upon retirement, if the stock award has been held for at least one year by the recipient. In accordance with the terms of our stock grants, for employees who will become retirement eligible prior to the vest date we expense stock-based awards, other than performance-based and market-based awards, over the greater of one year or the period between grant date and retirement-eligibility. The performance-based and market-based awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirement-eligibility. We recognize stock-based compensation expense for the value of the portion of awards that are ultimately expected to vest. FASB ASC Topic 718, Compensation – Stock Compensation allows forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock-based award. We have applied, based on an analysis of our historical forfeitures, a weighted-average annual forfeiture rate of approximately five percent to all unvested stock-based awards as of December 31, 2022, which represents the portion that we expect will be forfeited each year over the vesting period. We re-evaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest. Unrecognized Compensation Cost We expect to recognize the following future expense for awards outstanding as of December 31, 2022: Unrecognized Compensation Cost (in millions) (1) Weighted Average Remaining Vesting Period (in years) Stock options $ 38 Non-vested stock awards 181 $ 219 1.7 (1) Amounts presented represent compensation cost, net of estimated forfeitures. Employee Stock Purchase Plan In May 2022, our stockholders approved an additional 10 million shares that may be issued under our global employee stock purchase plan. Our global employee stock purchase plan now provides for the granting of options to purchase up to 60 million shares of our common stock to all eligible employees. Under the global employee stock purchase plan, we grant each eligible employee, at the beginning of each six-month offering period, an option to purchase shares of our common stock equal to not more than ten percent of the employee’s eligible compensation or the statutory limit under the U.S. Internal Revenue Code. Such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period, at a purchase price equal to 85 percent of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. As of December 31, 2022, there were approximately 11 million shares available for future issuance under the employee stock purchase plan. We temporarily suspended our global employee stock purchase plan for the offering period for the second half of 2020 due to cost-savings initiatives in response to the COVID-19 pandemic and resumed the plan beginning with the offering period for the first half of 2021. Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows: Year Ended December 31, 2022 2021 2020 Shares issued or to be issued (in thousands) 2,850 2,578 1,387 Range of purchase prices $ 31.68 - $ 32.31 $ 29.98 - $ 36.11 $ 29.84 Expense recognized (in millions) $ 28 $ 24 $ 10

Weighted Average Shares Outstan

Weighted Average Shares Outstanding	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
EARNINGS PER SHARE	NOTE L – WEIGHTED AVERAGE SHARES OUTSTANDING Year Ended December 31, (in millions) 2022 2021 2020 Weighted average shares outstanding - basic 1,430.5 1,422.3 1,416.7 Net effect of common stock equivalents 9.2 11.5 — Weighted average shares outstanding - assuming dilution 1,439.7 1,433.8 1,416.7 The following securities were excluded from the calculation of weighted average shares outstanding - assuming dilution because their effect in the periods presented below would have been antidilutive: Year Ended December 31, (in millions) 2022 2021 2020 Common stock equivalents (1) n/a n/a 14 Stock options outstanding (2) 6 3 6 MCPS (3) 24 24 14 (1) Represents common stock equivalents pursuant to our employee stock-based compensation plans, which are anti-dilutive in 2020 due to our Net loss position in this period. (2) Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods. (3) Represents common stock issuable upon the conversion of MCPS. Refer to Note J – Stockholders' Equity for additional information. We base Net income (loss) per common share - assuming dilution upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and MCPS from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive. In 2022, 2021 and 2020, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, Net income (loss) was reduced by cumulative Preferred stock dividends , as presented in our consolidated statements of operations, for purposes of calculating Net income (loss) available to common stockholders

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE M – SEGMENT REPORTING In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve, and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments. We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all excluding the impact of foreign currency. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes within our consolidated statements of operations and are included in the reconciliation below. Refer to Note N – Revenue for net sales by reportable segment presented in accordance with U.S. GAAP. A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). We have revised prior periods to conform to the current year presentation. Year Ended December 31, Net sales 2022 2021 2020 MedSurg $ 5,057 $ 4,616 $ 3,844 Cardiovascular 8,161 7,212 5,913 Total net sales of reportable segments 13,218 11,828 9,756 Other (1) (60) 13 219 Impact of foreign currency fluctuations (476) 47 (65) $ 12,682 $ 11,888 $ 9,913 Year Ended December 31, Income (loss) before income taxes 2022 2021 2020 MedSurg $ 1,625 $ 1,524 $ 1,156 Cardiovascular 2,113 1,888 1,043 Total operating income of reportable segments 3,737 3,412 2,198 Unallocated amounts: Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments (436) (406) (424) Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs (789) (1,070) (1,208) Amortization expense (803) (741) (789) Other (1) (60) 4 143 Operating income (loss) 1,649 1,199 (80) Other income (expense), net (508) (123) 1 Income (loss) before income taxes $ 1,141 $ 1,076 $ (79) (1) In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Operating income of reportable segments as a percentage of net sales of reportable segments Year Ended December 31, 2022 2021 2020 MedSurg 32.1 % 33.0 % 30.1 % Cardiovascular 25.9 % 26.2 % 17.6 % Year Ended December 31, Depreciation expense 2022 2021 2020 MedSurg $ 88 $ 91 $ 90 Cardiovascular 245 261 240 Total depreciation expense of reportable segments 333 352 330 Other (1) — — 3 Consolidated depreciation expense $ 333 $ 352 $ 333 As of December 31, Total assets 2022 2021 MedSurg $ 2,501 $ 2,178 Cardiovascular 5,205 4,417 Total assets of reportable segments 7,706 6,595 Goodwill 12,920 11,988 Other intangible assets, net 5,902 6,121 All other corporate assets 5,941 7,525 $ 32,469 $ 32,229 As of December 31, Long-lived assets 2022 2021 U.S. $ 1,241 $ 1,190 Ireland 478 436 Costa Rica 246 185 Other countries 481 440 Property, plant and equipment, net 2,446 2,252 Goodwill 12,920 11,988 Other intangible assets, net 5,902 6,121 Operating lease right-of-use assets in Other long-term assets 386 435 $ 21,653 $ 20,795

Revenue

Revenue	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	NOTE N – REVENUE We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our consolidated statements of operations. In the first quarter of 2022, we reorganized our business structure into five operating segments. The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation: Year Ended December 31, 2022 2021 2020 Businesses U.S. Int'l Total U.S. Int'l Total U.S. Int'l Total Endoscopy $ 1,341 $ 880 $ 2,221 $ 1,222 $ 919 $ 2,141 1,000 $ 780 $ 1,780 Urology 1,257 516 1,773 1,120 463 1,583 918 368 1,286 Neuromodulation 715 202 917 713 196 909 610 151 761 MedSurg 3,312 1,599 4,911 3,055 1,578 4,633 2,528 1,299 3,827 Interventional Cardiology Therapies 744 1,485 2,228 778 1,431 2,209 728 1,247 1,975 Watchman 915 103 1,019 729 100 829 253 71 324 Cardiac Rhythm Management 1,337 763 2,100 1,214 805 2,019 992 712 1,704 Electrophysiology 275 310 585 128 237 365 118 169 287 Cardiology 3,271 2,662 5,932 2,850 2,572 5,422 2,091 2,199 4,290 Peripheral Interventions 1,048 850 1,899 996 824 1,820 888 689 1,577 Cardiovascular 4,319 3,512 7,831 3,846 3,396 7,242 2,979 2,888 5,866 Other 1 — — (60) 10 4 13 193 27 219 Total Net Sales $ 7,632 $ 5,111 $ 12,682 $ 6,911 $ 4,978 $ 11,888 $ 5,701 $ 4,212 $ 9,913 (1) In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based. Refer to Note M – Segment Reporting for information on our reportable segments. Year Ended December 31, Geographic Regions 2022 2021 2020 U.S. $ 7,632 $ 6,901 $ 5,508 Europe, Middle East and Africa 2,526 2,518 2,097 Asia-Pacific 2,116 2,070 1,781 Latin America and Canada 469 386 307 Other 1 (60) 13 219 Total Net Sales $ 12,682 $ 11,888 $ 9,913 Emerging Markets (2) $ 1,715 $ 1,429 $ 1,138 (2) We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Türkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation. Contract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying consolidated balance sheets. Our deferred revenue balance was $509 million as of December 31, 2022 and $484 million as of December 31, 2021. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiac Rhythm Management (CRM) business, for which revenue is recognized over the average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $156 million in 2022 that was included in the above contract liability balance as of December 31, 2021. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred. We capitalize sales force commissions related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE™ Remote Monitoring Service. These fulfillment costs are amortized over the average service period. In 2020, we recorded $179 million in revenue reserves primarily related to our conversion to a consignment commercial model for our LAAC franchise with the launch of our next-generation WATCHMAN FLX™ Device in the U.S. In connection with the conversion, we repurchased customer-owned inventory and subsequently recognized revenue for consigned units as they were consumed. Refer to Note A – Significant Accounting Policies for additional information on our accounting policies relating to revenue recognition.

Changes in Other Comprehensive

Changes in Other Comprehensive Income	12 Months Ended
	Dec. 31, 2022
Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]
Comprehensive Income (Loss) Note [Text Block]	NOTE O – CHANGES IN OTHER COMPREHENSIVE INCOME The following table provides the reclassifications out of Other comprehensive income, net of tax : (in millions) Foreign Currency Translation Adjustments Net Change in Derivative Financial Instruments Net Change in Defined Benefit Pensions and Other Items Total Balance as of December 31, 2021 $ 93 $ 206 $ (36) $ 263 Other comprehensive income (loss) before reclassifications (86) 214 36 163 (Income) loss amounts reclassified from accumulated other comprehensive income (8) (150) 1 (157) Total other comprehensive income (loss) (94) 63 37 6 Balance as of December 31, 2022 $ (1) $ 269 $ 1 $ 269 (in millions) Foreign Currency Translation Adjustments Net Change in Derivative Financial Instruments Net Change in Defined Benefit Pensions and Other Items Total Balance as of December 31, 2020 $ 218 $ 36 $ (47) $ 207 Other comprehensive income (loss) before reclassifications 12 208 8 228 (Income) loss amounts reclassified from accumulated other comprehensive income (137) (38) 3 (173) Total other comprehensive income (loss) (125) 170 11 56 Balance as of December 31, 2021 $ 93 $ 206 $ (36) $ 263 Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustments and our cash flow hedges recorded in Net change in derivative financial instruments . The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from Accumulated other comprehensive income (loss), net of tax

New Accounting Pronouncements

New Accounting Pronouncements	12 Months Ended
	Dec. 31, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Pronouncements, Policy	NOTE P – NEW ACCOUNTING PRONOUNCEMENTS Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements. During 2022, we implemented the following standards, which did not have a material impact on our financial position or results of operations. ASC Update No. 2021-05 In July 2021, the FASB issued ASC Update No. 2021-05, Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments . The amendments in Update No. 2021-05 revise lessor lease classification guidance and require accounting for certain leases with variable lease payments that do not depend on a reference index or rate as operating leases. Such classification is required if the lease would have been classified as a sales-type or direct financing lease in accordance with guidance in FASB ASC Topic 842 and the lessor would have otherwise recognized a day-one loss. Update No. 2021-05 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We adopted Update No. 2021-05 in the first quarter of 2022 on a prospective basis. ASC Update No. 2022-06 In December 2022, the FASB issued ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. Update No. 2022-06 defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, in order to align with the March 2021 U.K. Financial Conduct Authority announcement that updated the intended cessation date of all currencies and tenors of the London Interbank Offered Rate (LIBOR) to June 30, 2023. Update No. 2022-06 was effective immediately at issuance. Standards to be Implemented In March 2022, the FASB issued ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. Update No. 2022-01 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities , for the corresponding period. We do not expect the adoption to have a material impact on our financial position or results of operations. In March 2022, the FASB issued ASC Update No. 2022-02, Financial Instruments- Credit Losses (Topic 326: Troubled Debt Restructurings and Vintage Disclosures. Update No. 2022-02 makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. Update No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Update No. 2022-02 should be applied prospectively, with the option of modified retrospective adoption for the recognition and measurement of troubled debt restructurings. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2016-13. We do not expect the adoption to have a material impact on our financial position or results of operations. In June 2022, the FASB issued ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance and the amendments in this update should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations. In September 2022, the FASB issued ASC Update No. 2022-04, Liabilities— Supplier Finance Programs (Subtopic 405-50). Update No. 2022-04 enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. Update No. 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on the newly required roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted and should be applied retrospectively to each period in which a balance sheet is presented, except for the amendment on roll forward information, which should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations. No other new accounting pronouncements, issued or effective in the period had or are expected to have a material impact on our consolidated financial statements.

Employee Retirement Plans (Note

Employee Retirement Plans (Notes)	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Compensation and Employee Benefit Plans [Text Block]	NOTE Q – EMPLOYEE RETIREMENT PLANS Defined Benefit Pension Plans Domestic Retirement Plans Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan. We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and other key contributors. Participants may retire with benefits once retirement conditions have been satisfied. U.K. Plan As a result of our 2019 acquisition of BTG plc. (BTG), we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom employees. During the second quarter of 2022, we transferred the benefit obligation and associated assets of the pension plan to third party insurers, and as a result, were relieved from primary responsibility of the benefit obligation and the related plan assets. The transaction did not have a material impact on our financial position or results of operations. Other International Retirement Plans In addition, we maintain retirement plans covering certain international employees. We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through OCI . As of December 31, 2022 and 2021, the funded status of our plans were unfunded or underfunded in aggregate. The outstanding obligation is as follows: As of December 31, 2022 ( in millions) Accumulated Benefit Obligation (ABO) Projected Fair value of Plan Assets Unfunded/Underfunded Domestic Retirement Plans $ 50 $ 55 $ — $ 55 Other International Retirement Plans 140 152 101 51 $ 190 $ 207 $ 101 $ 105 As of December 31, 2021 ( in millions) Accumulated Benefit Obligation (ABO) Projected Fair value of Plan Assets Unfunded/Underfunded PBO Recognized Domestic Retirement Plans $ 56 $ 59 $ — $ 59 U.K. Plan 209 209 205 3 Other International Retirement Plans 214 234 130 103 $ 478 $ 502 $ 336 $ 166 A rollforward of the changes in the PBO for our retirement plans is as follows: Year Ended December 31, (in millions) 2022 2021 Beginning obligations $ 502 $ 532 Acquired plans — 4 Service costs 13 17 Interest costs 3 3 Actuarial (gain) loss (54) (7) Plan curtailments/settlements (191) — Plan amendments and assumption changes (25) (6) Benefits paid (6) (22) Impact of foreign currency fluctuations (37) (20) Ending obligation $ 207 $ 502 The critical assumptions associated with our employee retirement plans for 2022 are as follows: Weighted Average Discount Rate Weighted Average Expected Return Weighted Average Rate of Compensation Increase (1) Domestic Retirement Plans 5.32% n/a 2.00% Other International Retirement Plans 2.62% 2.27% 3.00% (1) Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average. The critical assumptions associated with our employee retirement plans for 2021 are as follows: Weighted Average Discount Rate Weighted Average Expected Return Weighted Average Rate of Compensation Increase (1) Domestic Retirement Plans 2.40% n/a 1.50% U.K. Plan 0.70% 0.70% n/a Other International Retirement Plans 0.82% 2.16% 2.60% (1) Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average. A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows: Year Ended December 31, (in millions) 2022 2021 Beginning fair value $ 336 $ 355 Acquired plans — 1 Actual return on plan assets (2) 5 Employer contributions 16 12 Participant contributions 1 2 Plan curtailments/settlements (185) — Actuarial gain (loss) (25) (4) Benefits paid (9) (22) Impact of foreign currency fluctuations (32) (13) Ending fair value $ 101 $ 336 For our defined benefit plans, excluding our U.K. Plan, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments. Prior to the transfer, the U.K. Plan utilized the insurance buy-in methodology and based its discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2021. We believed this to be a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate was calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assumed that all pension increases would continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which would be based on Consumer Price Inflation (CPI). We based our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy was to invest in fully matching assets. This was achieved through the purchase of two buy-in policies (Buy-in contracts), which provided payments designed to equal all future benefit payments due from the fund. As of December 31, 2021, the Buy-in contracts represented 100 percent of the total plan assets, as compared to the target percentage of 100 percent, and are considered Level 3 investments. The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value: As of December 31, 2021 (in millions) Level 1 Level 2 Level 3 Total Buy-in contracts $ — $ — $ 205 $ 205 Total assets $ — $ — $ 205 $ 205 Changes in the fair value of the U.K. Plan Level 3 assets were as follows: (in millions) Buy-in Contracts Balance as of December 31, 2021 $ 205 Actual return on plan assets 0 Employer contributions 1 Plan curtailments/settlements (160) Actuarial gain (loss) (24) Benefits paid (2) Impact of foreign currency fluctuations (22) Balance as of December 31, 2022 $ — Expected benefit payments are estimated based on the same assumptions used in determining our benefit obligation as of December 31, 2022. Actual benefit payments will depend on future employment and compensation, average years employed and average life spans, in addition to other factors. Changes in any of these factors could significantly impact these estimated future benefit payments. Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows: (in millions) Post Retirement Benefits 2023 $ 15 2024 8 2025 13 2026 14 2027 14 2028 - 2032 70 Defined Contribution Plan We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $123 million in 2022, $118 million in 2021 and $102 million in 2020.

Schedule II

Schedule II	12 Months Ended
	Dec. 31, 2018
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	Description (in millions) Balance at Cumulative effect adjustment for adoption of ASU 2016-13 (1) Credit loss exposure (1) Write-offs (2) Balance at Year Ended December 31, 2022: Allowances for credit losses $ 108 n/a 35 (35) $ 109 Year Ended December 31, 2021: Allowances for credit losses $ 105 n/a 28 (25) $ 108 Year Ended December 31, 2020: Allowances for uncollectible accounts $ 74 10 49 (27) $ 105 (1) Following the adoption of FASB ASC Topic 326 as of January 1, 2020, we record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. Subsequent credit loss reserves are recorded when deemed uncollectible. Amounts shown within credit loss exposure above were established through selling, general and administrative expense. (2) Represents actual write-offs of uncollectible accounts.

Significant Accounting Polici_2

Significant Accounting Policies Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022
Significant Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]		Principles of Consolidation Our consolidated financial statements include the accounts of Boston Scientific Corporation and our subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE) . For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2022, 2021 or 2020. Basis of Presentation The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation S-X. Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.
Subsequent Events, Policy [Policy Text Block]		Subsequent Events We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions and Strategic Investments , Note I – Commitments and Contingencies and Note J – Stockholders' Equity .
Use of Estimates, Policy [Policy Text Block]		Accounting Estimates To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to Critical Accounting Estimates included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.
Cash and Cash Equivalents, Policy [Policy Text Block]		Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and Cash Equivalents We record Cash and cash equivalents in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash. Restricted Cash Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in Other current assets within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee. Restricted Cash Equivalents Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in Other current assets within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents are included in Other long-term assets
Concentration Risk Disclosure [Text Block]		Concentrations of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral. We record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account. We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2022, 2021 and 2020; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales. We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our Allowance for credit losses
Revenue Recognition, Policy [Policy Text Block]		Revenue Recognition We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers : • We have a contract with a customer that creates enforceable rights and obligations, • Promised products or services are identified, • The transaction price, or the amount we expect to receive, is determinable and • We have transferred control of the promised items to the customer. Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets. Deferred Revenue We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral. Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred. Variable Consideration We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates. We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above. Post-Implant Services We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to Selling, general and administrative expenses within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.
Standard Product Warranty, Policy		Warranty Obligations We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a
Inventory, Policy [Policy Text Block]		Inventories We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to Cost of products sold over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. During 2020, we recorded $149 million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID-19 pandemic and lower than forecasted demand for our products. We did not record any abnormal production variances during the years ended December 31, 2022 or 2021.
Property, Plant and Equipment, Policy [Policy Text Block]		Property, Plant and Equipment We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.
Business Combinations Policy [Policy Text Block]		Valuation of Business Combinations We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through Selling, general and administrative expenses . In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in Other, net equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition. Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through Contingent consideration net expense (benefit) on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.
In Process Research and Development, Policy [Policy Text Block]		Indefinite-lived Intangibles and IPR&D Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&D intangible assets acquired in a business combination. Our IPR&D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&D intangible asset. We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other. If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value. We use the income approach to determine the fair values of our IPR&D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See Note C – Goodwill and Other Intangible Assets for more information related to indefinite-lived intangibles, including IPR&D.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]		Amortization and Impairment of Intangible Assets We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20 years; amortizable technology-related and customer relationships, five to 25 years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets, and amortize over a two to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within Cost of products sold; Selling, general and administrative expenses and Research and development expenses, as appropriate within our accompanying consolidated statements of operations, and include in Amortization expense only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents. We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See Note C – Goodwill and Other Intangible Assets for more information related to impairments of intangible assets.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]		Goodwill Valuation We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, Intangibles - Goodwill and Other
Investment, Policy		Investments in Publicly Traded and Privately-Held Entities For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in Other, net within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, Investments - Equity Method and Joint Ventures . We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320 , Investments - Debt and Equity Securities . Refer to Note B – Acquisitions and Strategic Investments for additional details on our investment balances. Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. Net gains and losses and impairments associated with our investment portfolio are included within Other, net
Income Tax, Policy [Policy Text Block]		Income Taxes We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See Note H – Income Taxes for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.
Legal Costs, Policy [Policy Text Block]	In accordance with FASB ASC Topic 450, Contingencies , we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.	Legal and Product Liability Costs We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related charges (credits) in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our consolidated statements of operations. See Note I – Commitments and Contingencies for discussion of our individual material legal proceedings.
Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]		Costs Associated with Exit Activities We record employee termination costs in accordance with FASB ASC Topic 712 , Compensation - Nonretirement and Postemployment Benefits , if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB ASC Topic 420 , Exit or Disposal Cost Obligation s. We record such costs into expense over the employee’s future service period, if any. Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within Restructuring net charges (credits) in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within Costs of products sold, Selling, general and administrative expenses and Research and development expenses within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within Costs of products sold or Selling, general and administrative expenses
Foreign Currency Transactions and Translations Policy [Policy Text Block]		Translation of Foreign Currency We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of Accumulated other comprehensive income (loss), net of tax . We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar. Foreign currency transaction gains and losses are included within Other, net
Derivatives, Policy [Policy Text Block]		Financial Instruments We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815 , Derivatives and Hedging , and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to Note D – Hedging Activities and Fair Value Measurements for more information on our hedging instruments.
Research and Development Expense, Policy [Policy Text Block]		Research and Development We expense research and development (R&D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to Indefinite-lived Intangibles and IPR&D above for our policy regarding R&D projects acquired in connection with our business combinations and asset purchases.

Fair Value Measures and Disclos

Fair Value Measures and Disclosures (Policies)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Derivatives, Policy [Policy Text Block]	Financial Instruments We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815 , Derivatives and Hedging , and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to Note D – Hedging Activities and Fair Value Measurements for more information on our hedging instruments.
Fair Value Measurement, Policy [Policy Text Block]	FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures

Commitment and Contingencies (P

Commitment and Contingencies (Policies)	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Legal Costs, Policy [Policy Text Block]	In accordance with FASB ASC Topic 450, Contingencies , we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.	Legal and Product Liability Costs We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related charges (credits) in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our consolidated statements of operations. See Note I – Commitments and Contingencies for discussion of our individual material legal proceedings.

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
ASC Update No. 2020-10 Codification Improvements	ASC Update No. 2021-05 In July 2021, the FASB issued ASC Update No. 2021-05, Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments
ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method	In March 2022, the FASB issued ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. Update No. 2022-01 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities , for the corresponding period. We do not expect the adoption to have a material impact on our financial position or results of operations.
ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures)	In March 2022, the FASB issued ASC Update No. 2022-02, Financial Instruments- Credit Losses (Topic 326: Troubled Debt Restructurings and Vintage Disclosures. Update No. 2022-02 makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. Update No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Update No. 2022-02 should be applied prospectively, with the option of modified retrospective adoption for the recognition and measurement of troubled debt restructurings. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2016-13. We do not expect the adoption to have a material impact on our financial position or results of operations.
ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.	In June 2022, the FASB issued ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance and the amendments in this update should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.
ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50)	In September 2022, the FASB issued ASC Update No. 2022-04, Liabilities— Supplier Finance Programs (Subtopic 405-50). Update No. 2022-04 enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. Update No.
ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848	ASC Update No. 2022-06 In December 2022, the FASB issued ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. Update No. 2022-06 defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, in order to align with the March 2021 U.K. Financial Conduct Authority announcement that updated the intended cessation date of all currencies and tenors of the London Interbank Offered Rate (LIBOR) to June 30, 2023. Update No. 2022-06 was effective immediately at issuance.

Employee Retirement Plans Emplo

Employee Retirement Plans Employee Retirement Plans (Policies)	12 Months Ended
	Dec. 31, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]	We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through OCI

Acquisitions and Strategic In_2

Acquisitions and Strategic Investments (Tables)	12 Months Ended
	Dec. 31, 2022
Business Acquisition [Line Items]
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	We allocated a portion of the purchase price to the specific intangible asset categories as follows: Amount Assigned (in millions) Weighted Average Amortization Period (in years) Risk-Adjusted Discount Preventice: Amortizable intangible assets: Technology-related $ 215 9 10% Other intangible assets 22 8 10% $ 237 Lumenis: Amortizable intangible assets: Technology-related $ 388 12 11% Other intangible assets 35 11 11% Indefinite-lived intangible assets: IPR&D 69 N/A 12% $ 492 All Other: Amortizable intangible assets: Technology-related $ 465 12 16% - 17% Indefinite-lived intangible assets: IPR&D 43 N/A 17% $ 508
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Changes in the fair value of our contingent consideration liability were as follows: (in millions) Balance as of December 31, 2020 $ 196 Amount recorded related to current year acquisitions 440 Contingent consideration net expense (benefit) (136) Contingent consideration payments (15) Balance as of December 31, 2021 $ 486 Contingent consideration net expense (benefit) 35 Contingent consideration payments (371) Balance as of December 31, 2022 $ 149
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs: Contingent Consideration Liability Fair Value as of December 31, 2022 Valuation Technique Unobservable Input Range Weighted Average (1) R&D, Regulatory and Commercialization-based Milestones $13 million Discounted Cash Flow Discount Rate 1% - 2% 2% Probability of Payment 10% - 25% 22% Projected Year of Payment 2023 - 2025 2024 Revenue-based Payments $136 million Discounted Cash Flow Discount Rate 6 % - 14% 7% Probability of Payment 100% 100% Projected Year of Payment 2023 - 2024 2023 (1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Investment [Table Text Block]	The aggregate carrying amount of our strategic investments was comprised of the following: As of December 31, (in millions) 2022 2021 Equity method investments $ 188 $ 259 Measurement alternative investments (1) 216 142 Publicly-held securities (2) 2 10 Notes receivable 1 — $ 407 $ 412 (1) Measurement alternative investments are privately-held equity securities or agreements for future equity without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying consolidated statements of operations. (2) Publicly-held equity securities are measured at fair value with changes in fair value recognized in Other, net within our consolidated statements of operations.
Baylis Medical
Business Acquisition [Line Items]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	(in millions) Payment for acquisition, net of cash acquired $ 1,463 $ 1,463
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The final purchase price allocation was comprised of the following components: (in millions) Goodwill $ 988 Amortizable intangible assets 657 Other assets acquired 112 Liabilities assumed (287) Net deferred tax liabilities (7) $ 1,463
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	We allocated a portion of the purchase price to the specific intangible asset categories as follows: Amount Assigned (in millions) Weighted Average Amortization Period (in years) Risk-Adjusted Discount Amortizable intangible assets: Technology-related $ 622 11 11% Other intangible assets 36 11 11% $ 657
2021 Acquisitions
Business Acquisition [Line Items]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations . (in millions) Preventice Lumenis All Other Total Payment for acquisition, net of cash acquired $ 706 $ 1,032 $ 519 $ 2,258 Fair value of contingent consideration 221 — 218 440 Fair value of prior interest 269 — 287 556 $ 1,197 $ 1,032 $ 1,025 $ 3,254
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The final purchase price allocation for these acquisitions was comprised of the following components: (in millions) Preventice Lumenis All Other Total Goodwill $ 926 $ 534 $ 594 $ 2,053 Amortizable intangible assets 237 423 465 1,125 Indefinite-lived intangible assets — 69 43 112 Other assets acquired 65 297 9 372 Liabilities assumed (32) (282) (11) (325) Net deferred tax liabilities — (9) (75) (84) $ 1,197 $ 1,032 $ 1,025 $ 3,254

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill [Table Text Block]	The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows: As of December 31, 2022 As of December 31, 2021 (in millions) Gross Carrying Amount Accumulated Gross Carrying Amount Accumulated Technology-related $ 12,397 $ (7,378) $ 11,957 $ (6,754) Patents 486 (394) 494 (398) Other intangible assets 1,960 (1,400) 1,900 (1,325) Amortizable intangible assets $ 14,843 $ (9,173) $ 14,351 $ (8,476) Goodwill $ 22,820 $ (9,900) $ 21,888 $ (9,900) IPR&D 112 126 Technology-related 120 120 Indefinite-lived intangible assets $ 232 $ 246
Schedule of Goodwill [Table Text Block]	The following represents our goodwill balance by reportable segment. (in millions) MedSurg Cardiovascular Total Balance as of December 31, 2020 $ 3,707 $ 6,243 $ 9,951 Goodwill acquired 544 1,520 2,064 Foreign currency fluctuations and other changes (5) (21) (27) Balance as of December 31, 2021 $ 4,246 $ 7,741 $ 11,988 Goodwill acquired — 1,030 1,030 Foreign currency fluctuations and other changes (10) (88) (98) Balance as of December 31, 2022 $ 4,237 $ 8,684 $ 12,920
Schedule of Expected Amortization Expense [Table Text Block]	Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December 31, 2022 is as follows (in millions): Fiscal Year 2023 $ 781 2024 741 2025 683 2026 665 2027 625

Hedging Activities and Fair V_2

Hedging Activities and Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2022
Derivative [Line Items]
Schedule of Notional Amounts of Outstanding Derivative Positions (Table Text Block)	The following table presents the contractual amounts of our hedging instruments outstanding: (in millions) FASB ASC Topic 815 Designation As of December 31, 2022 2021 Forward currency contracts Cash flow hedge $ 2,725 $ 3,996 Forward currency contracts Net investment hedge 365 493 Foreign currency-denominated debt (1) Net investment hedge 997 997 Forward currency contracts Non-designated 4,235 3,892 Total Notional Outstanding $ 8,321 $ 9,378
Derivative Instruments, Gain (Loss) [Table Text Block]	The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to Note O – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss). Effect of Hedging Relationships on Accumulated Other Comprehensive Income Amount Recognized in OCI on Hedges Consolidated Statements of Operations (1) Amount Reclassified from AOCI into Earnings (in millions) Pre-Tax Gain (Loss) Tax Benefit (Expense) Gain (Loss) Net of Tax Location of Amount Reclassified and Total Amount of Line Item Pre-Tax (Gain) Loss Tax (Benefit) Expense (Gain) Loss Net of Tax Year Ended December 31, 2022 Forward currency contracts Cash flow hedges $ 276 $ (62) $ 214 Cost of products sold $ 3,956 $ (209) $ 47 $ (162) Net investment hedges (2) 41 (10) 32 Interest expense 470 (10) 2 (8) Foreign currency-denominated debt Net investment hedges (3) 61 (14) 47 Other, net 38 — — — Interest rate derivative contracts Cash flow hedges — — — Interest expense 470 16 (4) 13 Year Ended December 31, 2021 Forward currency contracts Cash flow hedges $ 268 $ (60) $ 208 Cost of products sold $ 3,711 $ (54) $ 12 $ (42) Net investment hedges (2) 56 (13) 43 Interest expense 341 (13) 3 (10) Foreign currency-denominated debt Net investment hedges (3) 82 (19) 64 Other, net (218) — — — Interest rate derivative contracts Cash flow hedges — — — Interest expense 341 5 (1) 4 Year Ended December 31, 2020 Forward currency contracts Cash flow hedges $ (99) $ 22 $ (77) Cost of products sold $ 3,465 $ (83) $ 19 $ (64) Net investment hedges (2) (37) 8 (29) Interest expense 361 (24) 5 (19) Foreign currency-denominated debt Net investment hedges (3) (89) 21 (68) Other, net (362) — — — Interest rate derivative contracts Cash flow hedges — — — Interest expense 361 5 (1) 4 (1) In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings. (2) For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings. (3) For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI . No amounts were reclassified from AOCI to current period earnings.
Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]	As of December 31, 2022, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions): Designated Hedging Instrument FASB ASC Topic 815 Designation Location on Consolidated Statements of Operations Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings Forward currency contracts Cash flow hedge Cost of products sold $ 223 Forward currency contracts Net investment hedge Interest expense 10 Interest rate derivative contracts Cash flow hedge Interest expense (3)
Derivatives Not Designated as Hedging Instruments (Table Text Block)	Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below: (in millions) Location on Consolidated Statements of Operations Year Ended December 31, 2022 2021 2020 Net gain (loss) on currency hedge contracts Other, net $ (53) $ (16) $ 73 Net gain (loss) on currency transaction exposures Other, net 21 (12) (105) Net currency exchange gain (loss) $ (31) $ (27) $ (32)
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Table Text Block)	The following are the balances of our derivative and nonderivative assets and liabilities: (in millions) Location on Consolidated Balance Sheets (1) As of December 31, 2022 2021 Derivative and Nonderivative Assets: Designated Hedging Instruments Forward currency contracts Other current assets $ 196 $ 183 Forward currency contracts Other long-term assets 149 169 345 352 Non-Designated Hedging Instruments Forward currency contracts Other current assets 36 42 Total Derivative and Nonderivative Assets $ 381 $ 394 Derivative and Nonderivative Liabilities: Designated Hedging Instruments Forward currency contracts Other current liabilities $ — $ 32 Forward currency contracts Other long-term liabilities 1 6 Foreign currency-denominated debt (2) Other long-term liabilities 952 1,011 953 1,049 Non-Designated Hedging Instruments Forward currency contracts Other current liabilities 52 22 Total Derivative and Nonderivative Liabilities $ 1,005 $ 1,071 (1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less. (2) Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and liabilities measured at fair value on a recurring basis consist of the following: As of December 31, 2022 December 31, 2021 (in millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Money market funds and time deposits $ 673 $ — $ — $ 673 $ 1,632 $ — $ — $ 1,632 Publicly-held securities 2 — — 2 10 — — 10 Hedging instruments — 381 — 381 — 394 — 394 Licensing arrangements — — 127 127 — — 246 246 $ 674 $ 381 $ 127 $ 1,182 $ 1,642 $ 394 $ 246 $ 2,282 Liabilities Hedging instruments $ — $ 1,005 $ — $ 1,005 $ — $ 1,071 $ — $ 1,071 Contingent consideration liability — — 149 149 — — 486 486 Licensing arrangements — — 159 159 — — 281 281 $ — $ 1,005 $ 308 $ 1,313 $ — $ 1,071 $ 767 $ 1,838 The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2022 include the following significant unobservable inputs: Licensing Arrangements Fair Value as of December 31, 2022 Valuation Technique Unobservable Input Range Weighted Average (1) Financial Asset $127 million Discounted Cash Flow Discount Rate 15% 15% Projected Year of Payment 2023 - 2025 2024 Financial Liability $159 million Discounted Cash Flow Discount Rate 12% - 15% 13% Projected Year of Payment 2023 - 2026 2024 (1) Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average. Changes in the fair value of our licensing arrangements' financial asset were as follows: (in millions) Balance as of December 31, 2020 $ 365 Proceeds from royalty rights (163) Fair value adjustment (expense) benefit 44 Balance as of December 31, 2021 $ 246 Proceeds from royalty rights (141) Fair value adjustment (expense) benefit 22 Balance as of December 31, 2022 $ 127 Changes in the fair value of our licensing arrangements' financial liability were as follows: (in millions) Balance as of December 31, 2020 $ 407 Payments for royalty rights (166) Fair value adjustment expense (benefit) 41 Balance as of December 31, 2021 $ 281 Payments for royalty rights (145) Fair value adjustment expense (benefit) 23 Balance as of December 31, 2022 $ 159

Contractual Obligations and C_2

Contractual Obligations and Commitments (Tables)	12 Months Ended
	Dec. 31, 2022
Short-term Debt [Line Items]
Schedule of Long-term Debt Instruments [Table Text Block]	Issuance Date Maturity Date As of December 31, Coupon Rate (1) (in millions, except interest rates) 2022 2021 October 2023 Senior Notes (4) August 2013 October 2023 $ — $ 244 4.125% March 2024 Notes (4) February 2019 March 2024 504 850 3.450% March 2025 Senior Notes (3) March 2022 March 2025 1,067 — 0.750% May 2025 Senior Notes (4) May 2015 May 2025 — 523 3.850% June 2025 Senior Notes May 2020 June 2025 500 500 1.900% March 2026 Senior Notes (4) February 2019 March 2026 255 850 3.750% December 2027 Senior Notes (3) November 2019 December 2027 960 1,021 0.625% March 2028 Senior Notes (3) March 2022 March 2028 800 — 1.375% March 2028 Senior Notes (4) February 2018 March 2028 344 434 4.000% March 2029 Senior Notes (4) February 2019 March 2029 272 850 4.000% June 2030 Senior Notes May 2020 June 2030 1,200 1,200 2.650% March 2031 Senior Notes (3) March 2022 March 2031 800 — 1.625% March 2034 Senior Notes (3) March 2022 March 2034 534 — 1.875% November 2035 Senior Notes (2) November 2005 November 2035 350 350 6.750% March 2039 Senior Notes (4) February 2019 March 2039 450 750 4.550% January 2040 Senior Notes December 2009 January 2040 300 300 7.375% March 2049 Senior Notes (4) February 2019 March 2049 650 1,000 4.700% Unamortized Debt Issuance Discount and Deferred Financing Costs 2023 - 2049 (76) (76) Unamortized Gain on Fair Value Hedges 2022 — 3 Finance Lease Obligation Various 5 6 Long-term debt $ 8,915 $ 8,804 Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges. (1) Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon. (2) Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective November 15, 2021, the interest rate payable decreased by 0.25 percent and began accruing at a rate of 6.75 percent following upgrades to our credit ratings. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings. (3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December 31, 2022 and 2021, respectively. (4) Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. In addition, in the first quarter of 2022, we repaid $250 million of 3.375% May 2022 Senior Notes classified within Current Debt Obligations within our consolidated balance sheets as of December 31, 2021.
Transfer of Financial Assets Accounted for as Sales [Table Text Block]	Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions): As of December 31, 2022 As of December 31, 2021 Factoring Arrangements Amount Weighted Average Interest Rate Amount Weighted Average Interest Rate Euro denominated $ 161 2.4 % $ 141 2.1 % Yen denominated 194 0.6 % 223 0.6 % Renminbi denominated 13 3.1 % 11 3.2 %
Long-term Purchase Commitment	Fiscal Year Unrecorded Purchase Obligations 2023 $ 755 2024 119 2025 71 2026 35 2027 19 Thereafter 21 $ 1,021
Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]	As of December 31, 2022, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility. Covenant Requirement Actual Maximum permitted leverage ratio (1) 3.75 times 2.57 times (1) Ratio of total debt to deemed consolidated EBITDA, as defined by the credit agreements, as amended.
Contractual Obligation, Fiscal Year Maturity	Contractual maturities of our long-term debt outstanding as of December 31, 2022 are as follows: Fiscal Year 2023 $ — 2024 504 2025 1,567 2026 255 2027 960 Thereafter 5,700
Commercial Paper [Member]
Short-term Debt [Line Items]
Schedule of Short-term Debt [Table Text Block]	Commercial Paper Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December 31, 2022 and 2021.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Supplemental Balance Sheet Information Related to Leases	The following table presents supplemental balance sheet information related to our operating leases: As of December 31, (in millions) 2022 2021 Assets Operating lease right-of-use assets in Other long-term assets $ 386 $ 435 Liabilities Operating lease liabilities in Other current liabilities 61 71 Operating lease liabilities in Other long-term liabilities 347 389
Lease, Cost	The following table presents the weighted average remaining lease term and discount rate information related to our operating leases: As of December 31, 2022 2021 Weighted average remaining lease term 10 years 10 years Weighted average discount rate 3.3% 2.6%
Supplemental Cash Flow Information Related to Leases	The following table presents supplemental cash flow information related to our operating leases: Year Ended December 31, (in millions) 2022 2021 Cash paid for amounts included in the measurement of operating lease liabilities Operating cash flows from operating leases $ 91 $ 87
Maturities of Lease Liabilities	The following table presents the maturities of our operating lease liabilities as of December 31, 2022 (in millions): Fiscal year Operating Leases 2023 $ 80 2024 66 2025 55 2026 43 2027 34 Thereafter 214 Total future minimum operating lease payments 492 Less: imputed interest (84) Present value of operating lease liabilities $ 408

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	12 Months Ended
	Dec. 31, 2022
Supplemental Balance Sheet Information [Abstract]
Trade accounts receivable, net [Table Text Block]	Trade accounts receivable, net As of December 31, (in millions) 2022 2021 Trade accounts receivable $ 2,079 $ 1,886 Allowance for credit losses (109) (108) $ 1,970 $ 1,778 The following is a rollforward of our Allowance for credit losses : Year Ended December 31, (in millions) 2022 2021 2020 Beginning balance $ 108 $ 105 $ 74 Cumulative effect adjustment for adoption of ASU 2016-13 n/a n/a 10 Credit loss expense 35 28 49 Write-offs (35) (25) (27) Ending balance $ 109 $ 108 $ 105
Schedule of Inventory, Current	Inventories As of December 31, (in millions) 2022 2021 Finished goods $ 1,171 $ 1,029 Work-in-process 147 128 Raw materials 548 452 $ 1,867 $ 1,610
Schedule of Other Current Assets [Table Text Block]	Other current assets As of December 31, (in millions) 2022 2021 Restricted cash and restricted cash equivalents $ 149 $ 188 Derivative assets 232 226 Licensing arrangements 60 132 Other 290 254 $ 731 $ 799
Property, plant and equipment, net [Table Text Block]	Property, plant and equipment, net As of December 31, (in millions) 2022 2021 Land $ 137 $ 109 Buildings and improvements 1,695 1,523 Equipment, furniture and fixtures 3,297 3,287 Capital in progress 598 605 5,728 5,525 Less: accumulated depreciation 3,282 3,273 $ 2,446 $ 2,252
Schedule of Other Assets [Table Text Block]	Other long-term assets As of December 31, (in millions) 2022 2021 Restricted cash equivalents $ 48 $ 55 Operating lease right-of-use assets 386 435 Derivative assets 149 169 Investments 407 412 Licensing arrangements 67 114 Indemnification asset 172 — Other 271 225 $ 1,500 $ 1,410
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses As of December 31, (in millions) 2022 2021 Legal reserves $ 231 $ 264 Payroll and related liabilities 830 848 Rebates 352 350 Contingent consideration 74 289 Other 674 686 $ 2,160 $ 2,436
Other Current Liabilities [Table Text Block]	Other current liabilities As of December 31, (in millions) 2022 2021 Deferred revenue $ 220 $ 208 Licensing arrangements 79 138 Taxes payable 232 209 Other 230 228 $ 761 $ 783
Other long-term liabilities [Table Text Block]	Other long-term liabilities As of December 31, (in millions) 2022 2021 Accrued income taxes $ 597 $ 442 Legal reserves 212 284 Contingent consideration 75 197 Licensing arrangements 80 143 Operating lease liabilities 347 389 Deferred revenue 289 276 Other 434 489 $ 2,035 $ 2,220

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Our Income (loss) before income taxes consisted of the following: Year Ended December 31, (in millions) 2022 2021 2020 Domestic $ (1,119) $ (648) $ (660) Foreign 2,260 1,724 581 $ 1,141 $ 1,076 $ (79)
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The related expense (benefit) for income taxes consisted of the following: Year Ended December 31, (in millions) 2022 2021 2020 Current Federal $ 51 $ 18 $ (29) State 19 33 (35) Foreign 381 127 151 451 178 87 Deferred Federal (92) (256) (26) State (32) (3) (6) Foreign 117 117 (53) (7) (142) (85) $ 443 $ 36 $ 2
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Significant components of our deferred tax assets and liabilities are as follows: As of December 31, (in millions) 2022 2021 Deferred Tax Assets: Inventory costs and related reserves $ 19 $ 10 Tax benefit of net operating losses and credits 511 620 Reserves and accruals 304 324 Restructuring-related charges 6 14 Litigation and product liability reserves 103 127 Investment write-down 38 31 Compensation related 136 130 Federal benefit of uncertain tax positions 9 8 Intangible assets 3,668 3,546 Capitalized R&D 160 67 Property, plant and equipment 2 14 Other — 35 4,954 4,926 Less: valuation allowance (1,004) (1,014) 3,950 3,912 Deferred Tax Liabilities: Unrealized gains and losses on derivative financial instruments 117 79 Other 34 — 151 79 Net Deferred Tax Assets 3,799 3,833 Prepaid on intercompany profit 264 205 Net Deferred Tax Assets and Prepaid on Intercompany Profit $ 4,062 $ 4,038 Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions): Location on Consolidated Balance Sheets As of December 31, Component 2022 2021 Prepaid on intercompany profit Prepaid income taxes $ 264 $ 205 Non-current deferred tax asset Deferred tax assets 3,942 4,142 Deferred Tax Assets and Prepaid on Intercompany Profit 4,206 4,348 Non-current deferred tax liability Deferred tax liabilities 144 310 Deferred Tax Liabilities 144 310 Net Deferred Tax Assets and Prepaid on Intercompany Profit $ 4,062 $ 4,038
Summary of Income Tax Contingencies [Table Text Block]	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended December 31, (in millions) 2022 2021 2020 Beginning Balance $ 255 $ 261 $ 455 Additions based on positions related to the current year 88 8 28 Additions based on positions related to prior years 177 41 6 Reductions for tax positions of prior years (20) (36) (186) Settlements with taxing authorities (1) (2) (27) Statute of limitation expirations (8) (17) (15) Ending Balance $ 492 $ 255 $ 261
Tax rate	The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows: Year Ended December 31, 2022 2021 2020 U.S. federal statutory income tax rate 21.0 % 21.0 % (21.0) % State income taxes, net of federal benefit 0.7 % 2.5 % 16.6 % Domestic taxes on foreign earnings 15.3 % 6.8 % 155.4 % Effect of foreign taxes (3.8) % (14.3) % (40.7) % Acquisition-related 4.4 % (8.1) % (16.7) % Research credit (4.5) % (3.0) % (43.0) % Valuation allowance (1.3) % 0.8 % (42.0) % Goodwill impairment charges — % — % 3.7 % Compensation-related 0.6 % (0.6) % (7.7) % Non-deductible expenses 0.4 % 0.4 % 64.4 % Uncertain tax positions 7.7 % 1.2 % (96.8) % Intra-entity asset transfers — % — % 10.2 % Return to provision (2.1) % (5.7) % (37.3) % Change in tax rates (0.2) % 1.9 % 51.8 % Other, net 0.7 % 0.4 % 6.0 % 38.9 % 3.3 % 2.9 %

Stock Incentive and Purchase Pl

Stock Incentive and Purchase Plans (Tables)	12 Months Ended
	Dec. 31, 2022
Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items]
Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block]	The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December 31, 2022: 2022 AFCF 2021 AFCF 2020 AFCF Fair value, net of forfeitures to date (in millions) $ 7 $ 12 $ 6 Achievement of target payout 88 % 131 % 89 % Year-end stock price used in determining fair value $ 46.27 $ 42.48 $ 35.95
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following presents the impact of stock-based compensation on our consolidated statements of operations: Year Ended December 31, (in millions, except per share data) 2022 2021 2020 Cost of products sold $ 12 $ 11 $ 9 Selling, general and administrative expenses 167 147 130 Research and development expenses 41 36 30 220 194 170 Income tax (benefit) expense (32) (29) (28) $ 188 $ 165 $ 142 Net impact per common share - basic $ 0.13 $ 0.12 $ 0.10 Net impact per common share - assuming dilution $ 0.13 $ 0.12 $ 0.10
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions: Year Ended December 31, 2022 2021 2020 Options granted (in thousands) 3,287 3,822 3,819 Weighted-average exercise price $ 44.02 $ 37.69 $ 41.79 Weighted-average grant-date fair value $ 13.64 $ 10.77 $ 10.44 Black-Scholes Assumptions Expected volatility 28 % 29 % 23 % Expected term (in years, weighted) 6.1 5.9 5.8 Risk-free interest rate 1.42% - 3.87% 0.66% - 1.20% 0.27% - 1.72%
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	Information related to non-vested stock awards is as follows: Non-Vested Stock Award Units (in thousands) Weighted Average Balance as of December 31, 2019 11,079 $ 29 Granted 3,609 41 Vested (1) (4,147) 25 Forfeited (554) 34 Balance as of December 31, 2020 9,987 $ 34 Granted 4,240 $ 39 Vested (1) (3,823) $ 31 Forfeited (658) 36 Balance as of December 31, 2021 9,745 $ 37 Granted 3,854 $ 45 Vested (1) (3,482) $ 36 Forfeited (680) 44 Balance as of December 31, 2022 9,438 $ 41 (1) The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]	Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows: Year Ended December 31, 2022 2021 2020 Shares issued or to be issued (in thousands) 2,850 2,578 1,387 Range of purchase prices $ 31.68 - $ 32.31 $ 29.98 - $ 36.11 $ 29.84 Expense recognized (in millions) $ 28 $ 24 $ 10
Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]	We expect to recognize the following future expense for awards outstanding as of December 31, 2022: Unrecognized Compensation Cost (in millions) (1) Weighted Average Remaining Vesting Period (in years) Stock options $ 38 Non-vested stock awards 181 $ 219 1.7 (1) Amounts presented represent compensation cost, net of estimated forfeitures.
Market-based awards, valuation assumptions [Table Text Block]	We determined the fair value of the market-based RSU and DSU awards to be approximately $12 million for 2022, $11 million for 2021 and $8 million for 2020. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions: 2022 2021 2020 Awards Awards Awards Stock price on date of grant $ 44.19 $ 37.50 $ 42.16 Measurement period (in years) 2.9 2.9 2.9 Risk-free rate 1.71 % 0.20 % 1.37 %
Share-based Compensation, Stock Options, Activity [Table Text Block]	Information related to stock options under stock incentive plans are as follows: Stock Options (in thousands) Weighted Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (in millions) Outstanding as of December 31, 2019 23,065 $ 19 Granted 3,819 42 Exercised (3,096) 13 Cancelled/forfeited (666) 27 Outstanding as of December 31, 2020 23,122 $ 24 Granted 3,822 38 Exercised (4,796) 13 Cancelled/forfeited (699) 26 Outstanding as of December 31, 2021 21,448 $ 29 Granted 3,287 44 Exercised (2,745) 17 Cancelled/forfeited (502) 34 Outstanding as of December 31, 2022 21,489 $ 32 5.9 297 Exercisable as of December 31, 2022 13,674 27 4.6 258 Expected to vest as of December 31, 2022 7,535 41 8.2 38 Total vested and expected to vest as of December 31, 2022 21,209 $ 32 5.9 $ 296

Weighted Average Shares Outst_2

Weighted Average Shares Outstanding (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	Year Ended December 31, (in millions) 2022 2021 2020 Weighted average shares outstanding - basic 1,430.5 1,422.3 1,416.7 Net effect of common stock equivalents 9.2 11.5 — Weighted average shares outstanding - assuming dilution 1,439.7 1,433.8 1,416.7
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following securities were excluded from the calculation of weighted average shares outstanding - assuming dilution because their effect in the periods presented below would have been antidilutive: Year Ended December 31, (in millions) 2022 2021 2020 Common stock equivalents (1) n/a n/a 14 Stock options outstanding (2) 6 3 6 MCPS (3) 24 24 14 (1) Represents common stock equivalents pursuant to our employee stock-based compensation plans, which are anti-dilutive in 2020 due to our Net loss position in this period. (2) Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods. (3) Represents common stock issuable upon the conversion of MCPS. Refer to Note J – Stockholders' Equity for additional information.

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). We have revised prior periods to conform to the current year presentation. Year Ended December 31, Net sales 2022 2021 2020 MedSurg $ 5,057 $ 4,616 $ 3,844 Cardiovascular 8,161 7,212 5,913 Total net sales of reportable segments 13,218 11,828 9,756 Other (1) (60) 13 219 Impact of foreign currency fluctuations (476) 47 (65) $ 12,682 $ 11,888 $ 9,913
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Year Ended December 31, Income (loss) before income taxes 2022 2021 2020 MedSurg $ 1,625 $ 1,524 $ 1,156 Cardiovascular 2,113 1,888 1,043 Total operating income of reportable segments 3,737 3,412 2,198 Unallocated amounts: Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments (436) (406) (424) Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs (789) (1,070) (1,208) Amortization expense (803) (741) (789) Other (1) (60) 4 143 Operating income (loss) 1,649 1,199 (80) Other income (expense), net (508) (123) 1 Income (loss) before income taxes $ 1,141 $ 1,076 $ (79) (1) In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.
Segment operating income as percentage of net sales [Table Text Block]	Operating income of reportable segments as a percentage of net sales of reportable segments Year Ended December 31, 2022 2021 2020 MedSurg 32.1 % 33.0 % 30.1 % Cardiovascular 25.9 % 26.2 % 17.6 % Year Ended December 31, Depreciation expense 2022 2021 2020 MedSurg $ 88 $ 91 $ 90 Cardiovascular 245 261 240 Total depreciation expense of reportable segments 333 352 330 Other (1) — — 3 Consolidated depreciation expense $ 333 $ 352 $ 333
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	As of December 31, Total assets 2022 2021 MedSurg $ 2,501 $ 2,178 Cardiovascular 5,205 4,417 Total assets of reportable segments 7,706 6,595 Goodwill 12,920 11,988 Other intangible assets, net 5,902 6,121 All other corporate assets 5,941 7,525 $ 32,469 $ 32,229
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]	As of December 31, Long-lived assets 2022 2021 U.S. $ 1,241 $ 1,190 Ireland 478 436 Costa Rica 246 185 Other countries 481 440 Property, plant and equipment, net 2,446 2,252 Goodwill 12,920 11,988 Other intangible assets, net 5,902 6,121 Operating lease right-of-use assets in Other long-term assets 386 435 $ 21,653 $ 20,795

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2022
Disaggregation of Revenue [Abstract]
Disaggregation of Revenue [Table Text Block]	The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation: Year Ended December 31, 2022 2021 2020 Businesses U.S. Int'l Total U.S. Int'l Total U.S. Int'l Total Endoscopy $ 1,341 $ 880 $ 2,221 $ 1,222 $ 919 $ 2,141 1,000 $ 780 $ 1,780 Urology 1,257 516 1,773 1,120 463 1,583 918 368 1,286 Neuromodulation 715 202 917 713 196 909 610 151 761 MedSurg 3,312 1,599 4,911 3,055 1,578 4,633 2,528 1,299 3,827 Interventional Cardiology Therapies 744 1,485 2,228 778 1,431 2,209 728 1,247 1,975 Watchman 915 103 1,019 729 100 829 253 71 324 Cardiac Rhythm Management 1,337 763 2,100 1,214 805 2,019 992 712 1,704 Electrophysiology 275 310 585 128 237 365 118 169 287 Cardiology 3,271 2,662 5,932 2,850 2,572 5,422 2,091 2,199 4,290 Peripheral Interventions 1,048 850 1,899 996 824 1,820 888 689 1,577 Cardiovascular 4,319 3,512 7,831 3,846 3,396 7,242 2,979 2,888 5,866 Other 1 — — (60) 10 4 13 193 27 219 Total Net Sales $ 7,632 $ 5,111 $ 12,682 $ 6,911 $ 4,978 $ 11,888 $ 5,701 $ 4,212 $ 9,913 (1) In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based. Refer to Note M – Segment Reporting for information on our reportable segments. Year Ended December 31, Geographic Regions 2022 2021 2020 U.S. $ 7,632 $ 6,901 $ 5,508 Europe, Middle East and Africa 2,526 2,518 2,097 Asia-Pacific 2,116 2,070 1,781 Latin America and Canada 469 386 307 Other 1 (60) 13 219 Total Net Sales $ 12,682 $ 11,888 $ 9,913 Emerging Markets (2) $ 1,715 $ 1,429 $ 1,138 (2) We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Türkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.

Changes in Other Comprehensiv_2

Changes in Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2022
Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The following table provides the reclassifications out of Other comprehensive income, net of tax : (in millions) Foreign Currency Translation Adjustments Net Change in Derivative Financial Instruments Net Change in Defined Benefit Pensions and Other Items Total Balance as of December 31, 2021 $ 93 $ 206 $ (36) $ 263 Other comprehensive income (loss) before reclassifications (86) 214 36 163 (Income) loss amounts reclassified from accumulated other comprehensive income (8) (150) 1 (157) Total other comprehensive income (loss) (94) 63 37 6 Balance as of December 31, 2022 $ (1) $ 269 $ 1 $ 269 (in millions) Foreign Currency Translation Adjustments Net Change in Derivative Financial Instruments Net Change in Defined Benefit Pensions and Other Items Total Balance as of December 31, 2020 $ 218 $ 36 $ (47) $ 207 Other comprehensive income (loss) before reclassifications 12 208 8 228 (Income) loss amounts reclassified from accumulated other comprehensive income (137) (38) 3 (173) Total other comprehensive income (loss) (125) 170 11 56 Balance as of December 31, 2021 $ 93 $ 206 $ (36) $ 263

Employee Retirement Plans (Tabl

Employee Retirement Plans (Tables)	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Pension and Other Postretirement Plans, Policy [Policy Text Block]	We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $123 million in 2022, $118 million in 2021 and $102 million in 2020.
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]	The outstanding obligation is as follows: As of December 31, 2022 ( in millions) Accumulated Benefit Obligation (ABO) Projected Fair value of Plan Assets Unfunded/Underfunded Domestic Retirement Plans $ 50 $ 55 $ — $ 55 Other International Retirement Plans 140 152 101 51 $ 190 $ 207 $ 101 $ 105 As of December 31, 2021 ( in millions) Accumulated Benefit Obligation (ABO) Projected Fair value of Plan Assets Unfunded/Underfunded PBO Recognized Domestic Retirement Plans $ 56 $ 59 $ — $ 59 U.K. Plan 209 209 205 3 Other International Retirement Plans 214 234 130 103 $ 478 $ 502 $ 336 $ 166
Schedule of Changes in Projected Benefit Obligations [Table Text Block]	A rollforward of the changes in the PBO for our retirement plans is as follows: Year Ended December 31, (in millions) 2022 2021 Beginning obligations $ 502 $ 532 Acquired plans — 4 Service costs 13 17 Interest costs 3 3 Actuarial (gain) loss (54) (7) Plan curtailments/settlements (191) — Plan amendments and assumption changes (25) (6) Benefits paid (6) (22) Impact of foreign currency fluctuations (37) (20) Ending obligation $ 207 $ 502
Schedule of Defined Benefit Plans Disclosures [Table Text Block]	The critical assumptions associated with our employee retirement plans for 2022 are as follows: Weighted Average Discount Rate Weighted Average Expected Return Weighted Average Rate of Compensation Increase (1) Domestic Retirement Plans 5.32% n/a 2.00% Other International Retirement Plans 2.62% 2.27% 3.00% (1) Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average. The critical assumptions associated with our employee retirement plans for 2021 are as follows: Weighted Average Discount Rate Weighted Average Expected Return Weighted Average Rate of Compensation Increase (1) Domestic Retirement Plans 2.40% n/a 1.50% U.K. Plan 0.70% 0.70% n/a Other International Retirement Plans 0.82% 2.16% 2.60% (1) Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.
Schedule of Changes in Fair Value of Plan Assets [Table Text Block]	A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows: Year Ended December 31, (in millions) 2022 2021 Beginning fair value $ 336 $ 355 Acquired plans — 1 Actual return on plan assets (2) 5 Employer contributions 16 12 Participant contributions 1 2 Plan curtailments/settlements (185) — Actuarial gain (loss) (25) (4) Benefits paid (9) (22) Impact of foreign currency fluctuations (32) (13) Ending fair value $ 101 $ 336 Prior to the transfer, the U.K. Plan utilized the insurance buy-in methodology and based its discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2021. We believed this to be a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate was calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assumed that all pension increases would continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which would be based on Consumer Price Inflation (CPI). We based our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy was to invest in fully matching assets. This was achieved through the purchase of two buy-in policies (Buy-in contracts), which provided payments designed to equal all future benefit payments due from the fund. As of December 31, 2021, the Buy-in contracts represented 100 percent of the total plan assets, as compared to the target percentage of 100 percent, and are considered Level 3 investments. The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value: As of December 31, 2021 (in millions) Level 1 Level 2 Level 3 Total Buy-in contracts $ — $ — $ 205 $ 205 Total assets $ — $ — $ 205 $ 205 Changes in the fair value of the U.K. Plan Level 3 assets were as follows: (in millions) Buy-in Contracts Balance as of December 31, 2021 $ 205 Actual return on plan assets 0 Employer contributions 1 Plan curtailments/settlements (160) Actuarial gain (loss) (24) Benefits paid (2) Impact of foreign currency fluctuations (22) Balance as of December 31, 2022 $ —
Schedule of Expected Benefit Payments	Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows: (in millions) Post Retirement Benefits 2023 $ 15 2024 8 2025 13 2026 14 2027 14 2028 - 2032 70

Significant Accounting Polici_3

Significant Accounting Policies Significant Accounting Policies (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Significant Accounting Policies [Line Items]
Selling, general and administrative expenses	$ 4,520	$ 4,359	$ 3,787
Production Related Impairments or Charges			$ 149
Payment of contingent consideration	371	$ 15
Farapulse
Significant Accounting Policies [Line Items]
Payment of contingent consideration	$ 114

Acquisitions and Strategic In_3

Acquisitions and Strategic Investments (Details)

2 Months Ended

12 Months Ended

Nov. 29, 2022 USD ($)

Jun. 15, 2022 USD ($)

Jun. 15, 2022 KRW (₩)

Nov. 08, 2021 USD ($)

Sep. 01, 2021 USD ($)

Aug. 06, 2021 USD ($)

Mar. 01, 2021 USD ($)

Feb. 23, 2023 USD ($)

Feb. 23, 2023 KRW (₩)

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Dec. 31, 2020 USD ($)

Feb. 20, 2023

Business Acquisition [Line Items]

Proceeds from disposal of certain businesses and assets

$ 5,000,000

$ 826,000,000

$ 15,000,000

Business Combination, Contingent Consideration, Liability

149,000,000

486,000,000

196,000,000

Goodwill

12,920,000,000

11,988,000,000

9,951,000,000

Payments to Acquire Businesses, Net of Cash Acquired

1,542,000,000

2,258,000,000

3,000,000

Fair value of contingent consideration

(149,000,000)

(486,000,000)

(196,000,000)

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases

0

440,000,000

0

Intangible asset impairment charges

132,000,000

370,000,000

460,000,000

Contingent consideration net expense (benefit)

35,000,000

(136,000,000)

(100,000,000)

Payment of contingent consideration

371,000,000

15,000,000

Goodwill impairment charges

0

$ 0

$ 73,000,000

Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Specialty Pharmaceuticals [Member]

Business Acquisition [Line Items]

Disposal Group, Including Discontinued Operation, Consideration

$ 800,000,000

Divestiture, agreement, transfer of facilities

5

Divestiture, agreement, transfer of global employees

280

Preventice Solutions, Inc. [Member]

Business Acquisition [Line Items]

Business Combination, Contingent Consideration, Liability

221,000,000

Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value

269,000,000

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net

1,197,000,000

Goodwill

926,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

237,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets

65,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

(32,000,000)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities

0

Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination

$ 925,000,000

Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage

22%

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

237,000,000

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

$ 216,000,000

Payments to Acquire Businesses, Net of Cash Acquired

706,000,000

706,000,000

Fair value of contingent consideration

(221,000,000)

Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain

196,000,000

Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest

$ 300,000,000

Preventice Solutions, Inc. [Member] | Technology-Based Intangible Assets [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 215,000,000

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

9 years

Preventice Solutions, Inc. [Member] | Technology-Based Intangible Assets [Member] | Weighted Average (Member)

Business Acquisition [Line Items]

Discount Rate, Fair Value Input

10%

Preventice Solutions, Inc. [Member] | Other Intangible Assets [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 22,000,000

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

8 years

Preventice Solutions, Inc. [Member] | Other Intangible Assets [Member] | Weighted Average (Member)

Business Acquisition [Line Items]

Discount Rate, Fair Value Input

10%

Farapulse, Inc.

Business Acquisition [Line Items]

Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination

$ 450,000,000

Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage

27%

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

$ 92,000,000

Payments to Acquire Businesses, Net of Cash Acquired

268,000,000

Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain

222,000,000

Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest

$ 125,000,000

Business Combination, Consideration Transferred, Additional Revenue Payment, period [Line Items]

3 years

Lumenis LTD

Business Acquisition [Line Items]

Business Combination, Contingent Consideration, Liability

$ 0

Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value

0

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net

1,032,000,000

Goodwill

534,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

423,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets

69,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets

297,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

(282,000,000)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities

(9,000,000)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

492,000,000

Payments to Acquire Businesses, Net of Cash Acquired

$ 1,032,000,000

1,032,000,000

Fair value of contingent consideration

0

Accrued Income Taxes, Noncurrent

183,000,000

Business Combination, Indemnification Assets, Amount as of Acquisition Date

177,000,000

Lumenis LTD | In Process Research and Development [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 69,000,000

Lumenis LTD | In Process Research and Development [Member] | Weighted Average (Member)

Business Acquisition [Line Items]

Discount Rate, Fair Value Input

12%

Lumenis LTD | Technology-Based Intangible Assets [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 388,000,000

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

12 years

Lumenis LTD | Technology-Based Intangible Assets [Member] | Weighted Average (Member)

Business Acquisition [Line Items]

Discount Rate, Fair Value Input

11%

Lumenis LTD | Other Intangible Assets [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 35,000,000

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

11 years

Lumenis LTD | Other Intangible Assets [Member] | Weighted Average (Member)

Business Acquisition [Line Items]

Discount Rate, Fair Value Input

11%

Devoro Medical, Inc.

Business Acquisition [Line Items]

Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination

$ 320,000,000

Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage

16%

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

$ 67,000,000

Payments to Acquire Businesses, Net of Cash Acquired

251,000,000

Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain

57,000,000

Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest

$ 80,000,000

All Other 2021 Acquisitions

Business Acquisition [Line Items]

Business Combination, Contingent Consideration, Liability

$ 218,000,000

Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value

287,000,000

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net

1,025,000,000

Goodwill

594,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

465,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets

43,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets

9,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

(11,000,000)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities

(75,000,000)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

508,000,000

Payments to Acquire Businesses, Net of Cash Acquired

519,000,000

Fair value of contingent consideration

(218,000,000)

All Other 2021 Acquisitions | In Process Research and Development [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 43,000,000

All Other 2021 Acquisitions | In Process Research and Development [Member] | Weighted Average (Member)

Business Acquisition [Line Items]

Discount Rate, Fair Value Input

17%

All Other 2021 Acquisitions | Technology-Based Intangible Assets [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 465,000,000

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

12 years

All Other 2021 Acquisitions | Technology-Based Intangible Assets [Member] | Minimum [Member]

Business Acquisition [Line Items]

Discount Rate, Fair Value Input

16%

All Other 2021 Acquisitions | Technology-Based Intangible Assets [Member] | Maximum [Member]

Business Acquisition [Line Items]

Discount Rate, Fair Value Input

17%

2021 Acquisitions

Business Acquisition [Line Items]

Business Combination, Contingent Consideration, Liability

$ 440,000,000

Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value

556,000,000

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net

3,254,000,000

Goodwill

2,053,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

1,125,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets

112,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets

372,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

(325,000,000)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities

(84,000,000)

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

417,000,000

Payments to Acquire Businesses, Net of Cash Acquired

2,258,000,000

Fair value of contingent consideration

(440,000,000)

Baylis Medical

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net

1,463,000,000

Goodwill

988,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

657,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets

112,000,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

(287,000,000)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities

(7,000,000)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

657,000,000

Payments to Acquire Businesses, Net of Cash Acquired

1,463,000,000

Baylis Medical | Technology-Based Intangible Assets [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 622,000,000

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

11 years

Baylis Medical | Technology-Based Intangible Assets [Member] | Weighted Average (Member)

Business Acquisition [Line Items]

Discount Rate, Fair Value Input

11%

Baylis Medical | Other Intangible Assets [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 36,000,000

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

11 years

Baylis Medical | Other Intangible Assets [Member] | Weighted Average (Member)

Business Acquisition [Line Items]

Discount Rate, Fair Value Input

11%

M.I. Tech Co., Ltd

Business Acquisition [Line Items]

Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value

$ 615,000,000

$ 230,000,000

₩ 291,200,000,000

Business Acquisition, Percentage of Voting Interests Acquired

64%

64%

M.I. Tech Co., Ltd | Subsequent Event [Member]

Business Acquisition [Line Items]

Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value | ₩

₩ 20

Acotec Scientific Holdings Limited | Subsequent Event [Member]

Business Acquisition [Line Items]

Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value

$ 520,000,000

Business Acquisition, Percentage of Voting Interests Acquired

65%

Apollo Endosurgery, Inc.

Business Acquisition [Line Items]

Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value

$ 10

Business Acquisition, Percentage of Voting Interests Acquired

100%

Farapulse

Business Acquisition [Line Items]

Payment of contingent consideration

$ 114,000,000

Contingent Consideration (Detai

Contingent Consideration (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Aug. 06, 2021
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases	$ 0	$ 440	$ 0
Payment of contingent consideration	371	15
Contingent consideration net expense (benefit)	35	(136)	(100)
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Business Combination, Contingent Consideration, Liability	149	$ 486	$ 196
2021 Acquisitions
Business Combination, Contingent Consideration Arrangements [Abstract]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	417
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Business Combination, Contingent Consideration, Liability	440
Farapulse, Inc.
Business Combination, Contingent Consideration Arrangements [Abstract]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				$ 92
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest				$ 125
Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Business Combination, Contingent Consideration, Liability	$ 13
Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
contingent consideration liability, probability of payment	100%
Business Combination, Contingent Consideration, Liability	$ 136
Minimum [Member] | Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
contingent consideration liability, probability of payment	10%
Discount Rate, Fair Value Input	1%
Minimum [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Discount Rate, Fair Value Input	6%
Maximum [Member] | Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
contingent consideration liability, probability of payment	25%
Discount Rate, Fair Value Input	2%
Maximum [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Discount Rate, Fair Value Input	14%
Weighted Average (Member) | Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
contingent consideration liability, probability of payment	22%
Discount Rate, Fair Value Input	2%
Weighted Average (Member) | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
contingent consideration liability, probability of payment	100%
Discount Rate, Fair Value Input	7%

Strategic Investments (Details)

Strategic Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Investments [Line Items]
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity	$ 232
Equity Method Investments	188	$ 259
Measurement alternative investments (1)	216	142
Equity Securities, FV-NI	2	10
Notes receivable	1	0
Investments	407	$ 412
Unrealized Gain (Loss) on Investments	$ 178

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Other Intangible Assets
Finite-Lived Intangible Assets, Gross	$ 14,843	$ 14,351
Finite-Lived Intangible Assets, Accumulated Amortization	(9,173)	(8,476)
Goodwill, Gross	22,820	21,888
Goodwill, Impaired, Accumulated Impairment Loss	(9,900)	(9,900)
Indefinite-lived Intangible Assets (Excluding Goodwill)	232	246
Intangible asset impairment charges	132	370	$ 460
Goodwill (Roll Forward)
Goodwill	12,920	11,988	9,951
Goodwill, Translation and Purchase Accounting Adjustments	(98)	(27)
Goodwill, Acquired During Period	1,030	2,064
Goodwill, Impairment Loss	0	0	(73)
Other Intangible Assets (Textuals) [Abstract]
Future Amortization Expense, Year One	781
Future Amortization Expense, Year Two	741
Future Amortization Expense, Year Three	683
Future Amortization Expense, Year Four	665
Future Amortization Expense, Year Five	625
MedSurg [Member]
Goodwill (Roll Forward)
Goodwill	4,237	4,246	3,707
Goodwill, Translation and Purchase Accounting Adjustments	(10)	(5)
Goodwill, Acquired During Period	0	544
Cardiovascular [Member]
Goodwill (Roll Forward)
Goodwill	8,684	7,741	$ 6,243
Goodwill, Translation and Purchase Accounting Adjustments	(88)	(21)
Goodwill, Acquired During Period	1,030	1,520
In Process Research and Development [Member]
Goodwill and Other Intangible Assets
Indefinite-lived Intangible Assets (Excluding Goodwill)	112	126
Technology-Based Intangible Assets [Member]
Goodwill and Other Intangible Assets
Indefinite-lived Intangible Assets (Excluding Goodwill)	120	120
Technology-Based Intangible Assets [Member]
Goodwill and Other Intangible Assets
Finite-Lived Intangible Assets, Gross	12,397	11,957
Finite-Lived Intangible Assets, Accumulated Amortization	(7,378)	(6,754)
Patents [Member]
Goodwill and Other Intangible Assets
Finite-Lived Intangible Assets, Gross	486	494
Finite-Lived Intangible Assets, Accumulated Amortization	(394)	(398)
Other Intangible Assets [Member]
Goodwill and Other Intangible Assets
Finite-Lived Intangible Assets, Gross	1,960	1,900
Finite-Lived Intangible Assets, Accumulated Amortization	$ (1,400)	$ (1,325)

Fair Value Measurements (Detail

Fair Value Measurements (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) units	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net	$ 8	$ 24
Derivative, Notional Amount	8,321	9,378
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	(214)	(208)
Cost of Goods and Services Sold	3,956	3,711	$ 3,465
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	150	38
Interest Expense	470	341	361
Other Operating Income (Expense), Net	38	(218)	(362)
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax	8	137
Derivative Asset, Fair Value, Gross Asset	381	394
Derivative Liability, Fair Value, Gross Liability	1,005	1,071
Net currency exchange gain (loss)	(194)	0	0
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities, FV-NI	2	10
Derivative Asset	149	169
Licensing arrangements, asset	67	114
Business Combination, Contingent Consideration, Liability	149	486	196
Cash	256	293
Debt Instrument, Fair Value Disclosure	8,203	10,196
Other Noncurrent Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Licensing arrangements, liability	80	143
November 2019 Aggregate Offering [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Long-term Debt | €				€ 900
December 2027 Notes [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Long-term Debt	$ 960	1,021
Debt Instrument, Interest Rate, Stated Percentage	0.625%
Licensing arrangement assets (Member)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate, Fair Value Input	15%
M.I. Tech Co., Ltd
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	$ 228
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Licensing arrangements, asset	127
Licensing arrangements, liability	159
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money Market Funds, at Carrying Value	673	1,632
Equity Securities, FV-NI	2	10
Derivative Asset	381	394
Licensing arrangements, asset	127	246
Assets, Fair Value Disclosure	1,182	2,282
Foreign Currency Contracts, Liability, Fair Value Disclosure	1,005	1,071
Business Combination, Contingent Consideration, Liability	149	486
Licensing arrangements, liability	159	281
Financial and Nonfinancial Liabilities, Fair Value Disclosure	1,313	1,838
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money Market Funds, at Carrying Value	673	1,632
Equity Securities, FV-NI	2	10
Derivative Asset	0	0
Licensing arrangements, asset	0	0
Assets, Fair Value Disclosure	674	1,642
Foreign Currency Contracts, Liability, Fair Value Disclosure	0	0
Business Combination, Contingent Consideration, Liability	0	0
Licensing arrangements, liability	0	0
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money Market Funds, at Carrying Value	0	0
Equity Securities, FV-NI	0	0
Derivative Asset	381	394
Licensing arrangements, asset	0	0
Assets, Fair Value Disclosure	381	394
Foreign Currency Contracts, Liability, Fair Value Disclosure	1,005	1,071
Business Combination, Contingent Consideration, Liability	0	0
Licensing arrangements, liability	0	0
Financial and Nonfinancial Liabilities, Fair Value Disclosure	1,005	1,071
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money Market Funds, at Carrying Value	0	0
Equity Securities, FV-NI	0	0
Derivative Asset	0	0
Licensing arrangements, asset	127	246
Assets, Fair Value Disclosure	127	246
Foreign Currency Contracts, Liability, Fair Value Disclosure	0	0
Business Combination, Contingent Consideration, Liability	149	486
Licensing arrangements, liability	159	281
Financial and Nonfinancial Liabilities, Fair Value Disclosure	308	767
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Licensing arrangement assets (Member)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Licensing arrangements, asset	127	246	365
Proceeds from Royalties Received	(141)	(163)
Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option	22	44
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Licensing arrangement liabilities (Member)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Licensing arrangements, liability	159	281	407
Payments for Royalties	(145)	(166)
Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option	23	41
Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments in Hedges, Assets, at Fair Value	345	352
Derivative Instruments in Hedges, Liabilities, at Fair Value	953	1,049
Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments in Hedges, Liabilities, at Fair Value	$ 952	1,011
Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member)
Derivative Instruments, Gain (Loss) [Line Items]
Forward Currency Contracts, Time to Maturity | units	48
Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Other Noncurrent Assets [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments in Hedges, Assets, at Fair Value	$ 149	169
Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Other Current Liabilities [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments in Hedges, Liabilities, at Fair Value	0	32
Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Other Noncurrent Liabilities [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments in Hedges, Liabilities, at Fair Value	1	6
Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Prepaid Expenses and Other Current Assets [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments in Hedges, Assets, at Fair Value	196	183
Not Designated as Hedging Instrument [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	(53)	(16)	73
Foreign Currency Transaction Gain (Loss), before Tax	21	(12)	(105)
Net gain (loss) from foreign currency transaction exposures	(21)	12	105
Net currency exchange gain (loss)	(31)	(27)	(32)
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	4,235	3,892
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Other Current Liabilities [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value	52	22
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Prepaid Expenses and Other Current Assets [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value	$ 36	42
Weighted Average (Member) | Licensing arrangement assets (Member)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate, Fair Value Input	15%
Weighted Average (Member) | Licensing arrangement liabilities (Member)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate, Fair Value Input	13%
Minimum [Member] | Licensing arrangement liabilities (Member)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate, Fair Value Input	12%
Maximum [Member] | Licensing arrangement liabilities (Member)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate, Fair Value Input	15%
Cash Flow Hedging [Member] | Foreign Exchange Contract (Member) | Cost of Sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$ 223
Cash Flow Hedging [Member] | Interest Rate Contract [Member] | Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net	(3)
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	2,725	3,996
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Cost of Sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax	276	268	(99)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax	(62)	(60)	22
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	214	208	(77)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	(209)	(54)	(83)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax	47	12	19
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	(162)	(42)	(64)
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Interest Rate Contract [Member] | Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax	0	0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax	0	0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	0	0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	16	5	5
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax	(4)	(1)	(1)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	13	4	4
Net Investment Hedging [Member] | Foreign Exchange Contract (Member) | Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net	10
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	365	493
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	41	56	(37)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax	(10)	(13)	8
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	32	43	(29)
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax	(10)	(13)	(24)
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax	2	3	5
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax	(8)	(10)	(19)
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign currency denominated in debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	997	997
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign currency denominated in debt [Member] | Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	61	82	(89)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax	(14)	(19)	21
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	47	64	(68)
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax	0	0	0
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax	0	0	0
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax	$ 0	$ 0	$ 0

Contractual Obligations and C_3

Contractual Obligations and Commitments (Details) € in Millions, $ in Millions		3 Months Ended	12 Months Ended
	May 27, 2020	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022	Dec. 31, 2022 Rate	Mar. 31, 2022 USD ($)	May 10, 2021 USD ($)	Dec. 31, 2020 EUR (€)
Debt Instrument [Line Items]
Total debt		$ 8,935	$ 8,935	$ 9,065
Debt, Current		20	20	261
Long-term Debt and Capital Lease Obligations		8,915	8,915	8,804
Deemed Consolidated EBITDA [Member]			1,000
Exclusion from EBITDA for Restructuring Charges		500	500
Restructuring charges remaining to be excluded from calculation of consolidated EBITDA		265	265
Litigation and Debt Exclusion from EBITDA		1,455	1,455
Letters of Credit Outstanding, Amount		135	135	134
Legal payments remaining to be excluded from calculation of consolidated EBITDA		866	866
Purchase Obligations, Future Minimum Payments Due, Current		755	755
Purchase Obligations, Future Minimum Payments, Due in Two Years		119	119
Purchase Obligations, Future Minimum Payments, Due in Three Years		71	71
Purchase Obligations, Future Minimum Payments, Due in Four Years		35	35
Purchase Obligations, Future Minimum Payments, Due in Five Years		19	19
Purchase Obligations, Future Minimum Payments, Due Thereafter		21	21
Purchase Obligations, Future Minimum Payments Due		1,021	1,021
Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months		0	0
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two		504	504
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three		1,567	1,567
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four		255	255
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five		960	960
Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five		5,700	5,700
Proceeds from long-term borrowings, net of debt issuance costs			3,270	0	$ 1,683
Gain (Loss) on Extinguishment of Debt		194
May 2022 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage									(3.375%)
Short-term Debt									$ 250
Actual, Covenant [Member]
Debt Instrument [Line Items]
Maximum Leverage Ratio							2.57
Requirement, as of March 31, 2021
Debt Instrument [Line Items]
Maximum Leverage Ratio							3.75
Requirement, as of December 31, 2021 and through remaining term of facility
Debt Instrument [Line Items]
Maximum Leverage Ratio							3.75
Requirement, four quarters following material acquisition
Debt Instrument [Line Items]
Maximum Leverage Ratio							4.75
Requirement, fifth quarter following qualified acquisition [Member]
Debt Instrument [Line Items]
Maximum Leverage Ratio							4.50
Requirement, sixth quarter and thereafter following qualified acquisition [Member]
Debt Instrument [Line Items]
Maximum Leverage Ratio							4.25
Requirement, seventh quarter following qualified acquisition
Debt Instrument [Line Items]
Maximum Leverage Ratio							4
Requirement, eighth quarter and thereafter following qualified acquisition
Debt Instrument [Line Items]
Maximum Leverage Ratio							3.75
the 2018 Facility [Domain] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity										$ 2,750
November 2019 Aggregate Offering [Member]
Debt Instrument [Line Items]
Long-term Debt | €											€ 900
May 2022 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(4.125%)
Long-term Debt		0	0	244
October 2023 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(3.45%)
Long-term Debt		504	504	850
March 2024 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(0.75%)
Long-term Debt		1,067	1,067	0
May 2025 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(3.85%)
Long-term Debt		0	0	523
June 2025 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(1.90%)
Long-term Debt		500	500	500
March 2026 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(3.75%)
Long-term Debt		255	255	850
December 2027 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(0.625%)
Long-term Debt		960	960	1,021
March 2028 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(4.00%)
Long-term Debt		344	344	434
March 2029 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(4.00%)
Long-term Debt		272	272	850
June 2030 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(2.65%)
Long-term Debt		1,200	1,200	1,200
November 2035 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(6.75%)
Long-term Debt		350	350	350
March 2039 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(4.55%)
Long-term Debt		450	450	750
January 2040 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(7.375%)
Long-term Debt		300	300	300
March 2049 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(4.70%)
Long-term Debt		650	650	1,000
Unamortized Gain on Fair Value Hedges
Debt Instrument [Line Items]
Long-term Debt		0	0	3
Finance Lease Obligation
Debt Instrument [Line Items]
Long-term Debt		5	5	6
Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net		76	76	76
Long-term Debt		8,986	8,986	9,121
March 2028 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(1.375%)	(1.375%)
Long-term Debt		800	800	0		€ 750
March 2031 Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(1.625%)	(1.625%)
Long-term Debt		800	800	0		750
March 2034 Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							(1.875%)	(1.875%)
Long-term Debt		534	534	0		500
the Offering - aggregate principal amount
Debt Instrument [Line Items]
Long-term Debt | €						3,000
March 2025 Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage | Rate								(0.75%)
Long-term Debt | €						€ 1,000
the Offering - early redemption of combined aggregate principal SN
Debt Instrument [Line Items]
Long-term Debt		3,275	3,275
Euro Denominated Factoring Arrangements [Member]
Debt Instrument [Line Items]
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized		161	$ 161	$ 141
Average interest rate of de-recognized receivables			2.40%	2.10%
Yen Denominated Factoring Arrangements [Member]
Debt Instrument [Line Items]
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized		194	$ 194	$ 223
Average interest rate of de-recognized receivables			0.60%	0.60%
Renminbi Denominated Factoring Arrangements [Member]
Debt Instrument [Line Items]
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized		$ 13	$ 13	$ 11
Average interest rate of de-recognized receivables			3.10%	3.20%
5.50% MCPS, Series A [Member]
Debt Instrument [Line Items]
Preferred Stock, Dividend Rate, Percentage	5.50%

Leases (Details)

Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Leased Assets [Line Items]
Operating Lease, Liability, Current	$ 61	$ 71
Operating Lease, Liability, Noncurrent	$ 347	$ 389
Operating Lease, Weighted Average Remaining Lease Term	10 years	10 years
Operating Lease, Weighted Average Discount Rate, Percent	3.30%	2.60%
Operating Lease, Cost	$ 91	$ 90	$ 92
Operating Lease, Payments	91	87
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	43	68
Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months	80
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two	66
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three	55
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four	43
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five	34
Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five	214
Lessee, Operating Lease, Liability, to be Paid	492
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(84)
Operating Lease, Liability	408
Operating Lease, Right-of-Use Asset	$ 386	$ 435
Operating Lease, Liability, Current	Other current liabilities	Other current liabilities
Minimum [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Term of Contract	1 year
Maximum [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Term of Contract	54 years
Lessee, Operating and Finance Leases, Option to Extend	10 years

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other Current Assets [Abstract]
Restricted cash and restricted cash equivalents included in Other current assets	$ 149	$ 188	$ 208
Derivative Asset, Current	232	226
Licensing arrangements	60	132
Other Assets, Miscellaneous, Current	290	254
Other Assets, Current	731	799
Trade accounts receivable, net
Trade accounts receivable	2,079	1,886
Allowance for credit losses	(109)	(108)
Trade accounts receivable, net	1,970	1,778
Allowance for doubtful accounts
Accounts Receivable, Allowance for Credit Loss (beginning balance)	108	105	74
Cumulative effect adjustment for adoption of ASC 2016-13			10
Net (credits) charges to expenses	35	28	49
Utilization of allowances	(35)	(25)	(27)
Accounts Receivable, Allowance for Credit Loss (ending balance)	109	108	105
Inventory, Net [Abstract]
Inventory, Finished Goods, Net of Reserves	1,171	1,029
Inventory, Work in Process, Net of Reserves	147	128
Inventory, Raw Materials, Net of Reserves	548	452
Inventories	1,867	1,610
Property, plant and equipment, net
Land	137	109
Buildings and improvements	1,695	1,523
Equipment, furniture and fixtures	3,297	3,287
Capital in progress	598	605
Property, plant and equipment	5,728	5,525
Less: accumulated depreciation	3,282	3,273
Property, plant and equipment, net	$ 2,446	$ 2,252
Supplemental Balance Sheet Information (Textuals)
Percent of finished goods at consignment	27%	30%
Depreciation	$ 333	$ 352	333
Other Assets, Noncurrent [Abstract]
Restricted Cash Equivalents included in Other long-term assets	48	55	52
Operating Lease, Right-of-Use Asset	386	435
Derivative Asset	149	169
Investments	407	412
Licensing arrangements, asset	67	114
Other, Other Long-term Assets	271	225
Other long-term assets (total)	1,500	1,410
Accrued expenses
Legal reserves	231	264
Payroll and related liabilities	830	848
Accrued Rebates, Current	352	350
Contingent consideration	74	289
Other	674	686
Accrued liabilities, current	2,160	2,436
Other Liabilities, Current [Abstract]
Deferred Revenue, Current	220	208
Accrued Royalties, Current	79	138
Taxes Payable, Current	232	209
Other Sundry Liabilities, Current	230	228
Other current liabilities	761	783
Other long-term liabilities
Operating Lease, Liability, Noncurrent	$ 347	$ 389
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities	Other long-term liabilities
Other long-term liabilities	$ 2,035	$ 2,220
Operating Lease, Liability, Noncurrent	$ 347	$ 389
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities	Other long-term liabilities
Cumulative effect adjustment for adoption of ASC 2016-13			$ 10
Indemnification asset	$ 172	$ 0
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]
Operating Lease, Right-of-Use Asset	$ 386	$ 435
Other Noncurrent Liabilities [Member]
Other long-term liabilities
Accrued Income Taxes, Noncurrent	597	442
Estimated Litigation Liability, Noncurrent	212	284
Business Combination, Contingent Consideration, Liability, Noncurrent	75	197
Licensing arrangements, liability	80	143
Deferred Revenue	289	276
Other Accrued Liabilities, Noncurrent	434	489
Accrued Income Taxes, Noncurrent	597	442
Estimated Litigation Liability, Noncurrent	212	284
Business Combination, Contingent Consideration, Liability, Noncurrent	75	197
Licensing arrangements, liability	80	143
Deferred Revenue	289	276
Other Accrued Liabilities, Noncurrent	$ 434	$ 489

Income Taxes (Details - Rate Ta

Income Taxes (Details - Rate Table)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Income Tax Rate Reconciliation [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	21%	21%	21%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes	0.70%	2.50%	16.60%
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent	15.30%	6.80%	155.40%
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential	(3.80%)	(14.30%)	(40.70%)
Effective Income Tax Rate Reconciliation, Nondeductible Expense	4.40%	8.10%	16.70%
Effective Income Tax Rate Reconciliation, Tax Credits, Research	(4.50%)	(3.00%)	(43.00%)
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance	(1.30%)	0.80%	(42.00%)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses	0%	0%	3.70%
effective income tax reconciliation, compensation-related	0.60%	(0.60%)	(7.70%)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent	0.40%	0.40%	64.40%
Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions	7.70%	1.20%	(96.80%)
Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers	0%	0%	10.20%
Effective Income Tax Rate Reconciliation, Return to provision	(2.10%)	(5.70%)	(37.30%)
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent	(0.20%)	1.90%	51.80%
Effective Income Tax Rate Reconciliation, Other Adjustments	0.70%	0.40%	6%
Reported tax rate	38.90%	3.30%	2.90%

Income Taxes Income Taxes (Deta

Income Taxes Income Taxes (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating Loss Carryforwards [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Domestic		$ (1,119)	$ (648)	$ (660)
Income (Loss) from Continuing Operations before Income Taxes, Foreign		2,260	1,724	581
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest		1,141	1,076	(79)
Current Federal Tax Expense (Benefit)		51	18	(29)
Current State and Local Tax Expense (Benefit)		19	33	(35)
Current Foreign Tax Expense (Benefit)		381	127	151
Current Income Tax Expense (Benefit)		451	178	87
Deferred Federal Income Tax Expense (Benefit)		(92)	(256)	(26)
Deferred State and Local Income Tax Expense (Benefit)		(32)	(3)	(6)
Deferred Foreign Income Tax Expense (Benefit)		117	117	(53)
Deferred Income Tax Expense (Benefit)		(7)	(142)	(85)
Income Tax Expense (Benefit)		443	36	2
Deferred Tax Assets, Inventory		19	10
Deferred Tax Assets, Operating Loss Carryforwards		511	620
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals		304	324
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges		6	14
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies		103	127
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses		38	31
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost		136	130
Federal benefit of uncertain tax positions		9	8
Deferred Tax Assets, Goodwill and Intangible Assets		3,668	3,546
Deferred Tax Assets, in Process Research and Development		160	67
Deferred Tax Assets, Property, Plant and Equipment		2	14
Deferred Tax Assets, Other		0	35
Deferred Tax Assets, Tax Deferred Expense		4,954	4,926
Deferred Tax Assets, Valuation Allowance		(1,004)	(1,014)
Deferred Tax Assets, Net of Valuation Allowance		3,950	3,912
Deferred Tax Liabilities, Derivatives		117	79
Deferred Tax Liabilities, Other		34	0
Deferred Tax Liabilities, Gross		151	79
Deferred Tax Assets, Gross		3,799	3,833
Deferred Tax Assets, Prepaid on Intercompany Profit		264	205
Net Deferred Tax Liabilities and Prepaid on Intercompany Profit		4,062	4,038
Deferred Tax Assets		4,206	4,348
Deferred Tax Liabilities, Net		144	310
Deferred Tax Assets, Operating Loss Carryforwards, Domestic		464	560
Deferred Tax Assets, Operating Loss Carryforwards, Foreign		47	60
Other Comprehensive Income (Loss), Tax		56	81	(78)
Free Trade Zone Regime Tax Incentive		162	149	64
Tax Incentives in Puerto Rico		21	27	30
Unrecognized Tax Benefits that Would Impact Effective Tax Rate		410	177	183
Unrecognized Tax Benefits		492	255	261	$ 455
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions		88	8	28
Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions		177	41	6
Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions		(20)	(36)	(186)
Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities		(1)	(2)	(27)
Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations		(8)	(17)	$ (15)
Tax Adjustments, Settlements, and Unusual Provisions	$ 91		62
Income Tax Examination, Penalties and Interest Accrued		77	43
Decrease in Unrecognized Tax Benefits is Reasonably Possible		75
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability		937	$ 938
One-time transaction tax post-1986 E&P - net payment		$ 586
Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution		$ 0.11	$ 0.10	$ 0.04
Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution		$ 0.02
transition tax payment remaining		$ 386
Tax incentives in Malaysia		$ 17	$ 0	$ 0
Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution		$ 0.01
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense		$ 14
Prepaid Expenses and Other Current Assets [Member]
Operating Loss Carryforwards [Line Items]
Deferred Tax Assets		264	205
Deferred tax assets [Domain]
Operating Loss Carryforwards [Line Items]
Deferred Tax Assets		3,942	4,142
Deferred tax liabilities [Domain]
Operating Loss Carryforwards [Line Items]
Deferred Tax Liabilities, Net		$ 144	$ 310

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions			12 Months Ended
	Jan. 31, 2023 USD ($)	Aug. 05, 2022 USD ($)	Dec. 31, 2022 USD ($) Unit	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Loss Contingencies [Line Items]
Accrual for legal matters that are probable and estimable			$ 443	$ 548
Restricted cash and restricted cash equivalents included in Other current assets			149	188	$ 208
Litigation Settlement, Expense			$ 173	$ 430	$ 278
Litigation Settlement, Amount Awarded to Other Party		$ 85
Brazil CADE - # of individuals for alleged anti-competitive behavior | Unit			29
Subsequent Event [Member]
Loss Contingencies [Line Items]
Litigation Settlement, Amount Awarded to Other Party	$ 42

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Millions			12 Months Ended
	Jan. 30, 2023	May 27, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 14, 2020
Class of Stock [Line Items]
Preferred Stock, Shares Authorized			50,000,000	50,000,000
Preferred Stock, Shares Issued			10,062,500	10,062,500
Net proceeds from issuance of preferred stock in connection with public offering			$ 0	$ 0	$ 975
Payments of Dividends			$ 55	$ 55	28
Common Stock, Shares Authorized			2,000,000,000	2,000,000,000
Common Stock, Par or Stated Value Per Share			$ 0.01	$ 0.01
Net proceeds from issuance of common stock in connection with public offering			$ 0	$ 0	$ 975
Stock Repurchase Program, Authorized Amount						$ 1,000
Stock Repurchase Program, Number of Shares Authorized to be Repurchased					15,700,000
Payments for repurchase of common stock			0	$ 0	$ 535
Dividends, Cash			$ 14
Treasury Stock, Shares			263,289,848	263,289,848
5.50% MCPS, Series A [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Issued		10,062,500
Preferred Stock, Dividend Rate, Percentage		5.50%
Preferred Stock, Liquidation Preference Per Share		$ 100	$ 100
Net proceeds from issuance of preferred stock in connection with public offering		$ 975
Preferred Stock, Liquidation Preference, Value			$ 1,006
Preferred Stock, Dividends, Per Share, Cash Paid			$ 1.3750
5.50% MCPS, Series A [Member] | Minimum [Member]
Class of Stock [Line Items]
Convertible Preferred Stock, Terms of Conversion			2.3834
5.50% MCPS, Series A [Member] | Maximum [Member]
Class of Stock [Line Items]
Convertible Preferred Stock, Terms of Conversion			2.9197
5.50% MCPS, Series A [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Preferred Stock, Dividends, Per Share, Cash Paid	$ 1.3750
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		29,382,500
Shares Issued, Price Per Share		$ 34.25
Net proceeds from issuance of common stock in connection with public offering		$ 975

Stock Incentive and Purchase _2

Stock Incentive and Purchase Plans (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Feb. 17, 2021	Oct. 01, 2020	Feb. 18, 2020	Dec. 31, 2019	Feb. 21, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of market based awards	$ 12	$ 11	$ 8
Share Price	$ 46.27	$ 42.48	$ 35.95	$ 44.19		$ 37.50		$ 42.16
Unrecognized Compensation Cost - Stock Options	$ 38
Stock Issued During Period, Shares, Employee Stock Purchase Plans	2,850,000	2,578,000	1,387,000
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased	$ 31.68	$ 29.98
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	9,438,000	9,745,000	9,987,000				11,079,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 41	$ 37	$ 34				$ 29
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	3,854,000	4,240,000	3,609,000
Measurement period - market based awards	2 years 10 months 24 days	2 years 10 months 24 days	2 years 10 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.71%	0.20%	1.37%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 45	$ 39	$ 41
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(3,482,000)	(3,823,000)	(4,147,000)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$ 36	$ 31	$ 25
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(680,000)	(658,000)	(554,000)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value	$ 44	$ 36	$ 34
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	21,489,000	21,448,000	23,122,000				23,065,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	3,287,000	3,822,000	3,819,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 44.02	$ 37.69	$ 41.79
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(2,745,000)	(4,796,000)	(3,096,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 17	$ 13	$ 13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	(502,000)	(699,000)	(666,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price	$ 34	$ 26	$ 27
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 297
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 10 months 24 days
Stock-based compensation expense	$ 220	$ 194	$ 170
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000
Common Stock, Capital Shares Reserved for Future Issuance	175,000,000
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	$ (32)	$ (29)	(28)
Share-based compensation, net of tax benefit	$ 188	$ 165	$ 142
compensation expense, per share - basic	$ 0.13	$ 0.12	$ 0.10
compensation expense, per share - diluted	0.13	0.12	0.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 13.64	$ 10.77	$ 10.44
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	28%	29%	23%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 1 month 6 days	5 years 10 months 24 days	5 years 9 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value	$ 72	$ 137	$ 84
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 32	$ 29	$ 24				$ 19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	13,674,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 27
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	4 years 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 258
Options expected to vest	7,535,000
Options expected to vest, weighted average exercise price	$ 41
Options expected to vest, weighted average remaining contractual life	8 years 2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value	$ 38
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	21,209,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 32
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	5 years 10 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$ 296
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value	$ 150	$ 148	$ 172
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	60,000,000
Amount of employees total compensation eligible for GESOP purchase	10%
Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)	85%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	11,000,000
Unrecognized Compensation Cost - Non-vested stock awards	$ 181
Unrecognized Compensation Cost	$ 219
weighted average remaining vesting period	1 year 8 months 12 days
annualweightedaverageforfeiturerate	5%
Voting power of all classes of stock	10%
Exercise price of the fair market value of our common stock on the date of grant	110%
Qualified options exercise price	$ 0
Fair value of the Free Cash Flow (FCF) performance awards	$ 7	$ 12	$ 6
Target payout of Free Cash Flows (FCF) performance awards	88%	131%	89%
Employee Stock Ownership Plan (ESOP), Compensation Expense	$ 28	$ 24	$ 10
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	10,000,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of the target number of performance-based DSUs awarded	0%
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased			$ 29.84
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.42%	0.66%	0.27%
Range of the target number of market-based DSUs awarded	0%
High end of range [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of the target number of performance-based DSUs awarded	150%
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased	$ 32.31	$ 36.11
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	3.87%	1.20%	1.72%
Range of the target number of market-based DSUs awarded	200%
2011 LTIP Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized					171,000,000
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 12	$ 11	$ 9
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	167	147	130
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 41	$ 36	$ 30

Weighted Average Shares Outst_3

Weighted Average Shares Outstanding (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted Average Number of Shares Outstanding, Basic	1,430,500	1,422,300	1,416,700
Weighted Average Number Diluted Shares Outstanding Adjustment	9,200	11,500	0
Weighted Average Number of Shares Outstanding, Diluted	1,439,700	1,433,800	1,416,700
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,000	3,000	6,000
5.50% MCPS, Series A [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	24,000	24,000	14,000
Share-based Payment Arrangement [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			14,000

Segment Reporting (Details)

Segment Reporting (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) reportablesegments	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | reportablesegments	2
Net sales	$ 12,682	$ 11,888	$ 9,913
Depreciation	333	352	333
Operating income allocated to reportable segments	1,649	1,199	(80)
Amortization expense	(803)	(741)	(789)
Other expense, net	(508)	(123)	1
Income (loss) before income taxes	1,141	1,076	(79)
Goodwill	12,920	11,988	9,951
Intangible Assets, Net (Excluding Goodwill)	5,902	6,121
Operating Lease, Right-of-Use Asset	386	435
Long-Lived Assets	21,653	20,795
Property, Plant and Equipment, Net	2,446	2,252
Impact of foreign currency fluctuations on net sales	(476)	47	(65)
Other
Segment Reporting Information [Line Items]
Net sales	(60)	13	219
Revenues from contracts with customers, disaggregated - performance measurement	(60)	13	219
United States [Member]
Segment Reporting Information [Line Items]
Net sales	7,632	6,911	5,701
Long-Lived Assets	1,241	1,190
United States [Member] | Other
Segment Reporting Information [Line Items]
Net sales	0	10	193
IRELAND
Segment Reporting Information [Line Items]
Long-Lived Assets	478	436
Other countries [Member]
Segment Reporting Information [Line Items]
Long-Lived Assets	481	440
COSTA RICA
Segment Reporting Information [Line Items]
Long-Lived Assets	246	185
MedSurg [Member]
Segment Reporting Information [Line Items]
Net sales	4,911	4,633	3,827
Depreciation	88	91	90
Operating Income (Loss) Allocated to Reportable Segments	$ 1,625	$ 1,524	$ 1,156
Segment operating income as percentage of net sales	32.10%	33%	30.10%
Assets (segment reporting)	$ 2,501	$ 2,178
Goodwill	4,237	4,246	$ 3,707
Revenues from contracts with customers, disaggregated - performance measurement	5,057	4,616	3,844
MedSurg [Member] | United States [Member]
Segment Reporting Information [Line Items]
Net sales	3,312	3,055	2,528
Cardiovascular [Member]
Segment Reporting Information [Line Items]
Net sales	7,831	7,242	5,866
Depreciation	245	261	240
Operating Income (Loss) Allocated to Reportable Segments	$ 2,113	$ 1,888	$ 1,043
Segment operating income as percentage of net sales	25.90%	26.20%	17.60%
Assets (segment reporting)	$ 5,205	$ 4,417
Goodwill	8,684	7,741	$ 6,243
Revenues from contracts with customers, disaggregated - performance measurement	8,161	7,212	5,913
Cardiovascular [Member] | United States [Member]
Segment Reporting Information [Line Items]
Net sales	4,319	3,846	2,979
BSX Reportable Segments
Segment Reporting Information [Line Items]
Depreciation	333	352	330
Revenues from contracts with customers, disaggregated - performance measurement	13,218	11,828	9,756
Total allocated to reportable segments [Member]
Segment Reporting Information [Line Items]
Operating income allocated to reportable segments	3,737	3,412	2,198
Assets (segment reporting)	7,706	6,595
Corporate Expenses including hedging activities [Member]
Segment Reporting Information [Line Items]
Operating Income Unallocated to Segment	(436)	(406)	(424)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs
Segment Reporting Information [Line Items]
Operating Income Unallocated to Segment	(789)	(1,070)	(1,208)
Corporate Segment
Segment Reporting Information [Line Items]
Assets (segment reporting)	5,941	7,525
Consolidated BSX [Domain]
Segment Reporting Information [Line Items]
Assets (segment reporting)	32,469	32,229
Other
Segment Reporting Information [Line Items]
Depreciation	0	0	3
Operating income allocated to reportable segments	$ (60)	$ 4	$ 143

Revenue (Details)

Revenue (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) countries	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Disaggregation of Revenue [Line Items]
Emerging Markets total number of countries | countries	20
Net sales	$ 12,682	$ 11,888	$ 9,913
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price			179
Contract with Customer, Liability [Abstract]
Contract with Customer, Liability	509	484
Change in Contract with Customer, Liability [Abstract]
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price			179
Contract with Customer, Liability, Revenue Recognized	156
UNITED STATES
Disaggregation of Revenue [Line Items]
Net sales	7,632	6,911	5,701
Non-US [Member]
Disaggregation of Revenue [Line Items]
Net sales	5,111	4,978	4,212
EMEA [Member]
Disaggregation of Revenue [Line Items]
Net sales	2,526	2,518	2,097
APAC [Member]
Disaggregation of Revenue [Line Items]
Net sales	2,116	2,070	1,781
Latin America and Canada [Member]
Disaggregation of Revenue [Line Items]
Net sales	469	386	307
Emerging Markets [Member]
Disaggregation of Revenue [Line Items]
Net sales	1,715	1,429	1,138
country_US excluding Other Net Sales
Disaggregation of Revenue [Line Items]
Net sales	7,632	6,901	5,508
Global Endoscopy (Endo) Reporting Unit [Member]
Disaggregation of Revenue [Line Items]
Net sales	2,221	2,141	1,780
Global Endoscopy (Endo) Reporting Unit [Member] | UNITED STATES
Disaggregation of Revenue [Line Items]
Net sales	1,341	1,222	1,000
Global Endoscopy (Endo) Reporting Unit [Member] | Non-US [Member]
Disaggregation of Revenue [Line Items]
Net sales	880	919	780
Global Urology and Pelvic Health Reporting Unit [Member]
Disaggregation of Revenue [Line Items]
Net sales	1,773	1,583	1,286
Global Urology and Pelvic Health Reporting Unit [Member] | UNITED STATES
Disaggregation of Revenue [Line Items]
Net sales	1,257	1,120	918
Global Urology and Pelvic Health Reporting Unit [Member] | Non-US [Member]
Disaggregation of Revenue [Line Items]
Net sales	516	463	368
Global Neuromodulation (NM) Reporting Unit [Member]
Disaggregation of Revenue [Line Items]
Net sales	917	909	761
Global Neuromodulation (NM) Reporting Unit [Member] | UNITED STATES
Disaggregation of Revenue [Line Items]
Net sales	715	713	610
Global Neuromodulation (NM) Reporting Unit [Member] | Non-US [Member]
Disaggregation of Revenue [Line Items]
Net sales	202	196	151
Global Peripheral Interventions (PI) Reporting Unit [Member]
Disaggregation of Revenue [Line Items]
Net sales	1,899	1,820	1,577
Global Peripheral Interventions (PI) Reporting Unit [Member] | UNITED STATES
Disaggregation of Revenue [Line Items]
Net sales	1,048	996	888
Global Peripheral Interventions (PI) Reporting Unit [Member] | Non-US [Member]
Disaggregation of Revenue [Line Items]
Net sales	850	824	689
Interventional Cardiology Therapies
Disaggregation of Revenue [Line Items]
Net sales	2,228	2,209	1,975
Interventional Cardiology Therapies | UNITED STATES
Disaggregation of Revenue [Line Items]
Net sales	744	778	728
Interventional Cardiology Therapies | Non-US [Member]
Disaggregation of Revenue [Line Items]
Net sales	1,485	1,431	1,247
Cardiac Rhythm Management
Disaggregation of Revenue [Line Items]
Net sales	2,100	2,019	1,704
Cardiac Rhythm Management | UNITED STATES
Disaggregation of Revenue [Line Items]
Net sales	1,337	1,214	992
Cardiac Rhythm Management | Non-US [Member]
Disaggregation of Revenue [Line Items]
Net sales	763	805	712
Electrophysiology (EP)
Disaggregation of Revenue [Line Items]
Net sales	585	365	287
Electrophysiology (EP) | UNITED STATES
Disaggregation of Revenue [Line Items]
Net sales	275	128	118
Electrophysiology (EP) | Non-US [Member]
Disaggregation of Revenue [Line Items]
Net sales	310	237	169
Watchman
Disaggregation of Revenue [Line Items]
Net sales	1,019	829	324
Watchman | UNITED STATES
Disaggregation of Revenue [Line Items]
Net sales	915	729	253
Watchman | Non-US [Member]
Disaggregation of Revenue [Line Items]
Net sales	103	100	71
Global Cardiology Reporting Unit
Disaggregation of Revenue [Line Items]
Net sales	5,932	5,422	4,290
Global Cardiology Reporting Unit | UNITED STATES
Disaggregation of Revenue [Line Items]
Net sales	3,271	2,850	2,091
Global Cardiology Reporting Unit | Non-US [Member]
Disaggregation of Revenue [Line Items]
Net sales	2,662	2,572	2,199
Other
Disaggregation of Revenue [Line Items]
Net sales	(60)	13	219
Other | UNITED STATES
Disaggregation of Revenue [Line Items]
Net sales	0	10	193
Other | Non-US [Member]
Disaggregation of Revenue [Line Items]
Net sales	0	4	27
MedSurg [Member]
Disaggregation of Revenue [Line Items]
Net sales	4,911	4,633	3,827
MedSurg [Member] | UNITED STATES
Disaggregation of Revenue [Line Items]
Net sales	3,312	3,055	2,528
MedSurg [Member] | Non-US [Member]
Disaggregation of Revenue [Line Items]
Net sales	1,599	1,578	1,299
Cardiovascular [Member]
Disaggregation of Revenue [Line Items]
Net sales	7,831	7,242	5,866
Cardiovascular [Member] | UNITED STATES
Disaggregation of Revenue [Line Items]
Net sales	4,319	3,846	2,979
Cardiovascular [Member] | Non-US [Member]
Disaggregation of Revenue [Line Items]
Net sales	$ 3,512	$ 3,396	$ 2,888

Changes in Other Comprehensiv_3

Changes in Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ (1)	$ 93	$ 218
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax	269	206	36
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax	1	(36)	(47)
Accumulated Other Comprehensive Income (Loss), Net of Tax	269	263	207
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(86)	12
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	214	208
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax	36	8
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	163	228
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax	(8)	(137)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	(150)	(38)
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax	1	3
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(157)	(173)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(94)	(125)	76
Net change in derivative financial instruments	63	170	(137)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax	(37)	(11)	1
Other Comprehensive Income (Loss), Net of Tax	$ 6	$ 56	$ (63)

Employee Retirement Plans (Deta

Employee Retirement Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Accumulated Benefit Obligation	$ 190	$ 478
Defined Benefit Plan, Benefit Obligation	207	502	$ 532
Defined Benefit Plan, Plan Assets, Amount	101	336	355
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position	105	166
Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets	0	1
Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets	0	4
Defined Benefit Plan, Service Cost	13	17
Defined Benefit Plan, Interest Cost	3	3
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment	(25)	(6)
pension benefit obligation, benefits paid	(6)	(22)
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	(37)	(20)
Defined Benefit Plan, Plan Assets, Payment for Settlement	(185)	0
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	(2)	5
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(54)	(7)
Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO	191	0
Defined Benefit Plan, Plan Assets, Contributions by Employer	16	12
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	1	2
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(25)	(4)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	(9)	(22)
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	(32)	(13)
Expense related to matching contributions	123	$ 118	$ 102
Defined Benefit Plan, Expected Future Benefit Payment, Year One	15
Defined Benefit Plan, Expected Future Benefit Payment, Year Two	8
Defined Benefit Plan, Expected Future Benefit Payment, Year Three	13
Defined Benefit Plan, Expected Future Benefit Payment, Year Four	14
Defined Benefit Plan, Expected Future Benefit Payment, Year Five	14
Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years	$ 70
Domestic Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Executive Retirement Plan Discount Rate	5.32%	2.40%
Executive Retirement Plan Rate of Compensation Increase	2%	1.50%
U.K. Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return		0.70%
Executive Retirement Plan Discount Rate		0.70%
Other International Plans
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return	2.27%	2.16%
Executive Retirement Plan Discount Rate	2.62%	0.82%
Executive Retirement Plan Rate of Compensation Increase	3%	2.60%
Fair Value, Inputs, Level 3 [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	$ (22)
Defined Benefit Plan, Plan Assets, Payment for Settlement	(160)
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	0
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(24)
Defined Benefit Plan, Plan Assets, Benefits Paid	(2)
Defined Benefit Plan, Plan Assets, Contributions by Employer	1
Other Contract
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Plan Assets, Amount		$ 205
Other Contract | Fair Value, Inputs, Level 1 [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Plan Assets, Amount		0
Other Contract | Fair Value, Inputs, Level 2 [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Plan Assets, Amount		0
Other Contract | Fair Value, Inputs, Level 3 [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Plan Assets, Amount		205
Executive retirement plan [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Accumulated Benefit Obligation	50	56
Defined Benefit Plan, Benefit Obligation	55	59
Defined Benefit Plan, Plan Assets, Amount	0	0
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position	55	59
International retirement plans [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Accumulated Benefit Obligation	140	214
Defined Benefit Plan, Benefit Obligation	152	234
Defined Benefit Plan, Plan Assets, Amount	101	130
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position	51	103
U.K. Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Accumulated Benefit Obligation		209
Defined Benefit Plan, Benefit Obligation		209
Defined Benefit Plan, Plan Assets, Amount	$ 0	205
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position		3
U.K. Plan | Fair Value, Inputs, Level 1 [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Plan Assets, Amount		0
U.K. Plan | Fair Value, Inputs, Level 2 [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Plan Assets, Amount		0
U.K. Plan | Fair Value, Inputs, Level 3 [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Defined Benefit Plan, Plan Assets, Amount		$ 205

Schedule II (Details)

Schedule II (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Accounts Receivable, Allowance for Credit Loss (beginning balance)	$ 108	$ 105	$ 74
Cumulative effect adjustment for adoption of ASC 2016-13			10
Net (credits) charges to expenses	35	28	49
Utilization of allowances	(35)	(25)	(27)
Accounts Receivable, Allowance for Credit Loss (ending balance)	$ 109	$ 108	105
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount			$ 105	$ 74